Split (3)

train · 29.5k rows

FEATURE_phases list	FEATURE_enrollmentCount int64	FEATURE_allocation string	FEATURE_interventionModel string	FEATURE_primaryPurpose class label	FEATURE_masking class label	FEATURE_healthyVolunteers bool	FEATURE_sex class label	FEATURE_oversightHasDmc bool	FEATURE_briefSummary string	FEATURE_detailedDescription string	FEATURE_conditions string	FEATURE_conditionsKeywords string	FEATURE_protocolPdfText string	FEATURE_numArms int64	FEATURE_armDescriptions string	FEATURE_armGroupTypes list	FEATURE_numInterventions int64	FEATURE_interventionTypes list	FEATURE_interventionDescriptions string	FEATURE_interventionNames string	FEATURE_numLocations int64	FEATURE_locationDetails string	LABEL_ct_level_ade_population int64	METADATA_nctId string	METADATA_overallStatus class label	METADATA_completionDate date32	METADATA_startDate date32	METADATA_leadSponsorName string	METADATA_leadSponsorClass class label	METADATA_hasProtocol bool	METADATA_hasSap bool	METADATA_hasIcf bool	METADATA_protocolPdfLinks string	METADATA_wilson_lower_bound float32
[ 4 ]	836	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to determine the long-term efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.	The drug that was tested in this study is called vortioxetine. Vortioxetine is being tested to treat depression in people who have major depressive disorder (MDD). This study looked at MDD relief in people who took vortioxetine. The study enrolled 836 patients that had completed one of two other vortioxetine studies. ...	Major Depressive Disorder	Major Depressive Disorder Depression Melancholia Mood Disorder Dysthymic Disorder Drug Therapy	null	1	arm 1: Vortioxetine 2.5 mg, 5 mg or 10 mg, encapsulated tablets, orally, once daily for up to 52 weeks. For the first week of treatment all participants received 5 mg/day vortioxetine, thereafter, the dose could be increased to 10 mg/day or decreased to 2.5 mg/day, based on participant's response and tolerability as ju...	[ 0 ]	1	[ 0 ]	intervention 1: Encapsulated vortioxetine immediate-release tablets	intervention 1: Vortioxetine	92	Beverly Hills \| California \| United States \| -118.40036 \| 34.07362 Irvine \| California \| United States \| -117.82311 \| 33.66946 Santa Ana \| California \| United States \| -117.86783 \| 33.74557 Torrance \| California \| United States \| -118.34063 \| 33.83585 Upland \| California \| United States \| -117.64839 \| 34.09751 Bradento...	834	NCT00707980	1COMPLETED	2010-08-01	2008-06-01	Takeda	4INDUSTRY	false	false	false	null	-0
[ 4 ]	441	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), compared to glipizide in elderly diabetic patients who have not received treatment or are on a single oral medication.	Type 2 diabetes is among the most common chronic condition in adults 65 years of age or older. A recent National Health and Nutrition Examination Survey reported that more than 20% of adults aged 65 years or older have diabetes. These individuals are often under-treated with respect to glucose-lowering medications, and...	Diabetes Mellitus	Glucose Metabolism Disorder Dysmetabolic Syndrome Type II Diabetes Diabetes Mellitus Lipoatrophic Dyslipidemia Drug Therapy	null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Alogliptin 25 mg, tablets, orally, once daily and glipizide placebo matching tablets, orally, once daily for up to 52 weeks. intervention 2: Alogliptin placebo-matching tablets, orally, once daily and glipizide 5 mg to 10 mg, tablets, orally, once daily up to 52 weeks.	intervention 1: Alogliptin intervention 2: Glipizide	80	Alexander City \| Alabama \| United States \| -85.95385 \| 32.94401 Foothill Ranch \| California \| United States \| -117.66088 \| 33.68641 Huntington Park \| California \| United States \| -118.22507 \| 33.98168 Long Beach \| California \| United States \| -118.18923 \| 33.76696 Los Angeles \| California \| United States \| -118.24368 \|...	441	NCT00707993	1COMPLETED	2010-08-01	2008-06-01	Takeda	4INDUSTRY	false	false	false	null	0
[ 2, 3 ]	8	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to determine the clinical and immunological effects of the phosphodiesterase type 4 inhibitor, CC-10004, on skin inflammation associated with cutaneous lupus erythematosus.	Discoid cutaneous lupus is the most common cutaneous manifestation of lupus erythematosus, a chronic, immune mediated disease of unknown etiology. The immune processes underlying cutaneous lupus remain largely unexplored, but recent evidence suggests a role for dendritic cells (DCs), type 1 interferons (IFN) and Th1-ty...	Discoid Lupus Erythematosus	Cutaneous lupus Intervention Discoid lupus Phosphodiesterase 5 inhibitor	null	1	arm 1: CC-10004 20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment	[ 0 ]	1	[ 0 ]	intervention 1: 20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment	intervention 1: CC-10004	1	New York \| New York \| United States \| -74.00597 \| 40.71427	8	NCT00708916	1COMPLETED	2010-08-01	2008-06-01	NYU Langone Health	7OTHER	false	false	false	null	0
[ 5 ]	23	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The consolidation of learning is enhanced by adrenalin and other stress hormones. This memory enhancing effect is opposed by propranolol. In posttraumatic stress disorder (PTSD), a psychologically traumatic event may overstimulate stress hormones such as adrenalin, which in turn overly strengthen consolidation of the m...	Background: Animal evidence indicates that some consolidated memories when reactivated (retrieved) need to be reconsolidated. During this process, memories can be enhanced or weakened. In a preliminary, randomized, double-blind, placebo-controlled study, we tested whether post-reactivation administration of the beta-ad...	Posttraumatic Stress Disorder	stress disorders post-traumatic memory propranolol psychophysiology	null	2	arm 1: 0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a "scrip...	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 0.67 mg/kg short-acting propranolol combined with 1 mg/kg long-acting propranolol intervention 2: Placebo (matching propranolol) short-acting and long-acting capsules	intervention 1: Propranolol intervention 2: Placebo	3	Bedford \| Massachusetts \| United States \| -71.27617 \| 42.49065 Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Manchester \| New Hampshire \| United States \| -71.45479 \| 42.99564	23	NCT00709735	1COMPLETED	2010-08-01	2007-05-01	Massachusetts General Hospital	7OTHER	false	false	false	null	0
[ 3 ]	14	RANDOMIZED	CROSSOVER	0TREATMENT	4QUADRUPLE	false	0ALL	true	It is hypothesized that oral naltrexone will improve inflammation of the bowel by increasing endogenous enkephalin levels in subjects with active Crohn's disease. This is especially important in children who often are suffering from nutritional deprivation which retards their growth. The key objectives are to: 1. Eva...	The present proposal is designed as double-blinded placebo controlled study involving 30 children between 6-17 years of age with active Crohn's disease. Children will be treated with either naltrexone or placebo for the first 8 weeks then all subjects will receive active naltrexone drug the last 8 weeks. A one month fo...	Crohn's Disease	children pediatric Crohn's Disease naltrexone LDN IBD Inflammatory bowel disease	null	2	arm 1: Subjects will receive placebo for for the first 8 weeks administered orally one time daily. After 8 weeks placebo treated subjects are then crossed over to active drug naltrexone 0.1 mg/kg not to exceed 4.5 mg PO once daily for an additional 8 weeks. arm 2: Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day o...	[ 2, 0 ]	2	[ 0, 10 ]	intervention 1: Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally for 16 weeks intervention 2: Placebo -Sugar pill or liquid identical to active drug in appearance and taste given by mouth at bedtime once daily	intervention 1: Naltrexone intervention 2: Placebo, sugar pill	1	Hershey \| Pennsylvania \| United States \| -76.65025 \| 40.28592	18	NCT00715117	1COMPLETED	2010-08-01	2008-07-01	Milton S. Hershey Medical Center	7OTHER	false	false	false	null	0
[ 0 ]	104	RANDOMIZED	PARALLEL	1PREVENTION	0NONE	false	0ALL	false	Patients requiring long term anticoagulation often undergo transition of their warfarin to heparin in anticipation of invasive surgical procedures such as pacemaker or ICD implantation. This may require inpatient hospitalization several days prior to and after the procedure, potentially increasing medical costs and pat...	null	Bradycardia Tachycardia Atrial Fibrillation Valvular Heart Disease	bleeding anticoagulation pacemaker implantable cardioverter-defibrillator patients undergoing implantation of a pacemaker or defibrillator (ICD)"	null	4	arm 1: Moderate risk patients (afib, mechanical aortic valve) randomized to continue coumadin at their usual dose through the procedure. arm 2: Moderate risk patients randomized to hold their coumadin for 4-5 days prior to the procedure (to allow the INR to normalize). arm 3: High risk patients (mechanical mitral valve...	[ 0, 1, 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period. intervention 2: For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure. intervention 3: For high risk patients, warfarin is held for 4-5 days prior to the procedure ...	intervention 1: continue warfarin through the procedure intervention 2: Hold warfarin intervention 3: Warfarin held with heparin transition.	2	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038 Columbia \| Maryland \| United States \| -76.83942 \| 39.24038	100	NCT00721136	1COMPLETED	2010-08-01	2007-09-01	Johns Hopkins University	7OTHER	false	false	false	null	0
[ 0 ]	1	NA	SINGLE_GROUP	6HEALTH_SERVICES_RESEARCH	0NONE	false	1FEMALE	false	The study examines and illustrates the utility of utilizing actigraphic measurements to assess treatment response.	Actigraphic measurements will be recorded every 30 seconds and will be recorded for an 11 day baseline period, followed by a 10 day period of the initial pharmacological interventions. The non-invasive nature of watch-like actigraphy devices is particularly attractive for use in pediatric populations. Meaningful treatm...	Sleep Disorders, Circadian Rhythm Insomnia Psychomotor Agitation	Kabuki Syndrome Actigraphy Treatment Response Measurement	null	1	arm 1: Actigraphic measurements were obtained by attaching an actigraphic watch device to the child's non-dominant wrist. The measurements will include three separate three week periods beginning with a baseline period and the period in which the child's pharmacological treatment was initiated. Two additional three wee...	[ 0 ]	1	[ 0 ]	intervention 1: Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).	intervention 1: risperidone	1	Fargo \| North Dakota \| United States \| -96.7898 \| 46.87719	1	NCT00723580	1COMPLETED	2010-08-01	2008-05-01	Child Psychopharmacology Institute	7OTHER	false	false	false	null	0
[ 4 ]	12	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	Evaluate pleiotropic effects of simvastatin in hypertensive patients.	null	Hypertension		null	4	arm 1: Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A) arm 2: Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B) arm 3: Participants who were administered Valsartan 80 mg plus simvastatin 40 mg ...	[ 1, 1, 0, 1 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 80 mg valsartan. Duration: 12 months. Tablets intervention 2: 40 mg pravastatin. Duration: 12 months. Tablets intervention 3: 40 mg simvastatin. Duration: 12 months. Tablets intervention 4: ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets	intervention 1: valsartan intervention 2: pravastatin intervention 3: simvastatin intervention 4: ezetimibe (+) simvastatin	0	null	11	NCT00738972	6TERMINATED	2010-08-01	2008-01-01	Fundación Lindavista del Corazón AC	7OTHER	false	false	false	null	0
[ 4 ]	227	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	Efficacy of BI 1356 compared to placebo in patients for whom metformin therapy is inappropriate (intolerability, contraindication). The second part of the study looks at the safety of BI 1356 in this patient population with longer term treatment in comparison to a sulfonylurea drug (glimepiride)	null	Diabetes Mellitus, Type 2		null	3	arm 1: 52 week treatment arm 2: First 18 weeks of treatment arm 3: Placebo patients switch to glimepiride week19-52	[ 0, 2, 1 ]	3	[ 0, 0, 0 ]	intervention 1: 5mg once daily intervention 2: 0 mg placebo comparator for part 1 of study (to 18 weeks) intervention 3: 1-4mg for part 2 of study (weeks 19-52)	intervention 1: Linagliptin intervention 2: Linagliptin Placebo intervention 3: Glimepiride	53	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Peoria \| Arizona \| United States \| -112.23738 \| 33.5806 Greenbrae \| California \| United States \| -122.5247 \| 37.94854 Harbor City \| California \| United States \| -118.29785 \| 33.79002 Huntington Park \| California \| United States \| -118.22507 \| 33.98168 Los Ange...	227	NCT00740051	1COMPLETED	2010-08-01	2008-08-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0
[ 0 ]	163	RANDOMIZED	PARALLEL	null	3TRIPLE	true	0ALL	true	The purpose of this study was to find out how varenicline works to help people quit smoking. Varenicline, also known as Chantix™, is an U.S. Food and Drug Administration (FDA) approved medication that has been shown to help people quit smoking. This study was trying to evaluate whether varenicline would change the resp...	We proposed the following primary hypotheses: 1. Tonic (i.e., non-cue-provoked) craving levels would be lower in participants receiving varenicline versus placebo. 2. Cue-provoked cravings (self-report and physiological responding) would be lower in participants receiving varenicline versus placebo. (Secondary indices...	Tobacco Dependence	tobacco nicotine smoking reward reinforcement craving cues conditioned stimuli cue reactivity	null	2	arm 1: For participants in the varenicline group, the medication doses followed the recommended dose schedule for the first 15 days of treatment: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day on days 8-15. arm 2: Participants in this group received a placebo instead of medication. ...	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Participants in this group received varenicline according to the schedule in the Arm Description. intervention 2: Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.	intervention 1: varenicline intervention 2: placebo	1	Tampa \| Florida \| United States \| -82.45843 \| 27.94752	163	NCT00747643	1COMPLETED	2010-08-01	2008-09-01	H. Lee Moffitt Cancer Center and Research Institute	7OTHER	false	false	false	null	0
[ 3, 4 ]	23	NON_RANDOMIZED	PARALLEL	9OTHER	0NONE	true	0ALL	false	Previously it was observed that individuals with tetraplegia have reduced baseline airway caliber and exhibit non-specific airway hyperresponsiveness (AHR). In persons with tetraplegia we have suggested that this is due to overriding cholinergic airway tone. In asthma, the mechanisms underlying bronchoconstriction and ...	The study requires a maximum of five study visits in the following order: 1. nebulized normal saline, 2. nebulized 1mg/kg of L-NAME (see below), 3. intravenous normal saline, 4. intravenous 1 mg/kg L-NAME, 5. intravenous 2 mg/kg L-Name.	Tetraplegia Asthma	Tetraplegia Mild asthma Exhaled Nitric Oxide NOS inhibitor Spinal cord injury Pulmonary Function	null	3	arm 1: Individuals with chronic tetraplegia arm 2: Individuals with diagnosed mild asthma arm 3: Neurologically intact, otherwise healthy, age-matched control	[ 0, 1, 2 ]	1	[ 0 ]	intervention 1: A non-specific inhibitor of the nitric oxide synthase enzyme.	intervention 1: N-Nitro L-arginine-methylester (L-NAME)	1	The Bronx \| New York \| United States \| -73.86641 \| 40.84985	23	NCT00753948	1COMPLETED	2010-08-01	2006-12-01	VA Office of Research and Development	1FED	false	false	false	null	0
[ 4 ]	241	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	1FEMALE	true	This trial will assess the efficacy and safety of PGL4001 with concomitant iron administration versus placebo with concomitant iron administration, over a 3-month period for the pre-operative treatment of pre-menopausal women suffering from excessive uterine bleeding due to uterine myoma.	null	Uterine Myomas		null	3	arm 1: PGL4001 5 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+ arm 2: PGL4001 10 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+ arm 3: PGL4001 matching placebo (oral tablets) with concomitant oral administration of 1 tablet containing ...	[ 0, 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: tablets intervention 2: tablets intervention 3: Tablets	intervention 1: PGL4001 (ulipristal) and iron intervention 2: PGL4001 matching placebo and iron intervention 3: PGL4001 (ulipristal) and iron	38	Brno \| N/A \| Czechia \| 16.60796 \| 49.19522 Prague \| N/A \| Czechia \| 14.42076 \| 50.08804 Prague \| N/A \| Czechia \| 14.42076 \| 50.08804 Prague \| N/A \| Czechia \| 14.42076 \| 50.08804 Békéscsaba \| N/A \| Hungary \| 21.1 \| 46.68333 Budapest \| N/A \| Hungary \| 19.04045 \| 47.49835 Budapest \| N/A \| Hungary \| 19.04045 \| 47.49835 Sze...	241	NCT00755755	1COMPLETED	2010-08-01	2008-10-01	PregLem SA	4INDUSTRY	false	false	false	null	0
[ 4 ]	240	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This is a local, multicenter, randomized, active comparator, double-blind, parallel group study with extension will be conducted to evaluate the efficacy and safety of celecoxib versus diclofenac SR in the treatment of Chinese patients with Ankylosing Spondylitis (AS).	null	Ankylosing Spondylitis		null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: capsule, 200 mg QD, 6-12 weeks intervention 2: tablet, 75 mg QD,6-12 weeks	intervention 1: Celecoxib intervention 2: Diclofenac SR	5	Guangzhou \| Guangdong \| China \| 113.25 \| 23.11667 Xi’an \| Shanxi \| China \| 113.52486 \| 35.99785 Chengdu \| Sichuan \| China \| 104.06667 \| 30.66667 Beijing \| N/A \| China \| 116.39723 \| 39.9075 Beijing \| N/A \| China \| 116.39723 \| 39.9075	456	NCT00762463	1COMPLETED	2010-08-01	2009-07-01	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	4INDUSTRY	false	false	false	null	0
[ 3 ]	15	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	This study is a double-blind, one center, two-arm study with a two (2) week Run-In, evaluating the efficacy of a once-daily administration of NanoDOX™ Hydrogel topically applied to diabetic ulcers in concert with professionally administered Standard of Care (SOC) procedures as described by Standard Operating Procedure(...	Study of NanoDOX vs placebo on diabetic ulcers of the lower leg/foot.	Diabetic Foot Ulcer	Diabetic Ulcer Wound	null	2	arm 1: 1.0% doxycycline gel arm 2: placebo gel	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 1.0% doxycycline gel applied topically to the wound once daily for 20 weeks intervention 2: placebo gel applied topically to the wound once daily for 20 weeks	intervention 1: doxycycline intervention 2: placebo gel	1	Gainesville \| Florida \| United States \| -82.32483 \| 29.65163	15	NCT00764361	1COMPLETED	2010-08-01	2009-01-01	NanoSHIFT LLC	4INDUSTRY	false	false	false	null	0
[ 2, 3 ]	9	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	Complications with current HIV antiretroviral therapy have left many children and adolescents with limited therapeutic options due to drug resistance. The purpose of this study is to test the effectiveness and safety of Vicriviroc (VCV), an HIV entry inhibitor and CCR5 co-receptor antagonist.	Highly active antiretroviral therapy (HAART) that includes a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI) has become the standard treatment of HIV-infected adults and children. When effective, HAART decreases the viral population, increases the body's immune responses, and leads t...	HIV Infections	Treatment Experienced	null	1	arm 1: HIV-1 Infected Antiretroviral Therapy Experienced Participants with CCR5-tropic Virus	[ 0 ]	1	[ 0 ]	intervention 1: Administered orally in either tablet or liquid form at a dosage of approximately 0.8/mg/kg every 24 hours, with a ritonavir boosted protease inhibitor containing background regimen	intervention 1: Vicriviroc	9	San Diego \| California \| United States \| -117.16472 \| 32.71571 Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511 Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 New York \| New York \| United States \| -74.0...	4	NCT00766597	1COMPLETED	2010-08-01	2009-08-01	National Institute of Allergy and Infectious Diseases (NIAID)	0NIH	false	false	false	null	0
[ 4 ]	116	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The primary objective of this study is to demonstrate the long-term safety and tolerability of MCI-196 in the subjects with stage V chronic kidney disease on dialysis with hyperphosphatemia. The secondary objective of this study is to assess the long-term efficacy of flexible doses of MCI-196.	null	Chronic Kidney Disease Dialysis Hyperphosphatemia	Chronic Kidney Disease Dialysis Hyperphosphatemia Phosphate binder	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: 3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose	intervention 1: MCI-196	21	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Orange \| California \| United States \| -117.85311 \| 33.78779 Tarzana \| California \| United States \| -118.55397 \| 34.17334 Orlando \| Florida \| United States \| -81.37924 \| 28.53834 Pembroke Pines \| Florida \| United States \| -80.22394 \| 26.00315 Atlanta \| Geo...	116	NCT00772382	1COMPLETED	2010-08-01	2008-12-01	Mitsubishi Tanabe Pharma Corporation	4INDUSTRY	false	false	false	null	0
[ 3 ]	15	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This phase II trial is studying how well R-(-)-gossypol acetic acid works in treating patients with recurrent extensive-stage small cell lung cancer. Drugs used in chemotherapy, such as R-(-)-gossypol acetic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them ...	PRIMARY OBJECTIVES: I. To determine the objective response rate of R-(-)-gossypol in patients with recurrent chemotherapy-sensitive extensive stage small cell lung cancer. II. To determine the time to disease progression. III. To determine the overall survival. IV. To assess the toxicities associated with this drug. ...	Extensive Stage Small Cell Lung Cancer Recurrent Small Cell Lung Cancer		null	1	arm 1: Patients receive oral R-(-)-gossypol once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	[ 0 ]	3	[ 0, 10, 10 ]	intervention 1: Given orally intervention 2: Correlative studies intervention 3: Correlative studies	intervention 1: R-(-)-gossypol acetic acid intervention 2: pharmacological study intervention 3: laboratory biomarker analysis	1	Rochester \| Minnesota \| United States \| -92.4699 \| 44.02163	15	NCT00773955	1COMPLETED	2010-08-01	2008-11-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0
[ 4 ]	189	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in treatment-naïve patients with (Genotype 1) hepatitis C.	null	Hepatitis C	Chronic Hepatitis C Protease Inhibitor Telaprevir Peginterferon Alfa-2b Ribavirin	null	2	arm 1: None arm 2: None	[ 0, 1 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: 750 mg every 8 hours for 12 weeks intervention 2: 600 - 1000 mg/day based on body weight for 24 weeks intervention 3: 1.5 mcg/kg/week for 24 weeks intervention 4: 600 - 1000 mg/day based on body weight for 48 weeks intervention 5: 1.5 mcg/kg/week for 48 weeks	intervention 1: MP-424 intervention 2: Ribavirin intervention 3: Peginterferon Alfa-2b intervention 4: Ribavirin intervention 5: Peginterferon Alfa-2b	1	Kawasaki \| Takatsu-ku \| Japan \| 139.71722 \| 35.52056	189	NCT00780416	1COMPLETED	2010-08-01	2008-11-01	Mitsubishi Tanabe Pharma Corporation	4INDUSTRY	false	false	false	null	0
[ 5 ]	60	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	This trial is conducted in Europe. The aim of this clinical trial is to compare the change in trunk fat mass, assessed by Double Energy X-ray Absorptiometry (DEXA) after 26 weeks of treatment with insulin detemir or insulin NPH (Neutral Protamine Hagedorn) (both combined with insulin aspart at the main meals) in overwe...	null	Diabetes Diabetes Mellitus, Type 2		null	2	arm 1: Insulin detemir injected subcutaneously (s.c.) in the evening in combination with insulin aspart injected s.c. as mealtime insulin for 26 weeks arm 2: Insulin isophane (Neutral Protamine Hagedorn, NPH) injected subcutaneously (s.c.) in the evening in combination with insulin aspart injected s.c. as mealtime insu...	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Insulin detemir once daily plus insulin aspart at mealtime intervention 2: Insulin NPH once daily plus insulin aspart at mealtime	intervention 1: insulin detemir intervention 2: insulin NPH	1	Málaga \| N/A \| Spain \| -4.42034 \| 36.72016	59	NCT00795600	1COMPLETED	2010-08-01	2009-04-01	Novo Nordisk A/S	4INDUSTRY	false	false	false	null	0
[ 3 ]	62	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This single arm study will assess the efficacy and safety of treatment with Xeloda plus standard pelvic radiotherapy in participants with locally advanced rectal cancer. Eligible participants will receive Xeloda 825mg/m\^2 orally twice daily plus standard radiotherapy for 5 weeks, followed by surgery within 6 weeks aft...	null	Colorectal Cancer		null	1	arm 1: Capecitabine orally twice daily plus standard radiotherapy for 5 weeks, followed by surgery within 6 weeks after completion of treatment.	[ 0 ]	2	[ 4, 0 ]	intervention 1: Administered as prescribed according to normal clinical practice. intervention 2: 825 milligrams per meter square (mg/m\^2) orally twice daily for 5 weeks.	intervention 1: Standard radiotherapy intervention 2: Capecitabine [Xeloda]	2	Banská Bystrica \| N/A \| Slovakia \| 19.15349 \| 48.73946 Bratislava \| N/A \| Slovakia \| 17.10674 \| 48.14816	62	NCT00796718	1COMPLETED	2010-08-01	2008-10-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0
[ 2, 3 ]	15	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	This is a global, multicenter, 2-part, open-label phase 1b and single-arm phase 2 study designed to evaluate the safety and efficacy of AMG 479 in combination with paclitaxel and carboplatin for the first-line treatment of advanced squamous non-small cell lung carcinoma.	null	Advanced Squamous Non-Small Cell Lung Cancer	AMG 479 IGF-1R Apoptosis Monoclonal Antibody Advanced Squamous Non-Small Cell Lung Cancer antibody 1st-line	Prot_SAP_000.pdf: Product: AMG479 Protocol Number: 20080257 Date: 02-September-2008 Page 1 of 114 Title: A Phase 1b/ 2 Study of AMG 479 in Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer AMG 479 Amgen Protocol Number 20080257 Cli...	3	arm 1: AMG 479 at 18 mg/kg in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 at 18 mg/kg monotherapy for 24 months from study day 1 arm 2: AMG 479 at 12 mg/kg in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 at 12 mg/kg monotherapy for 24 months from study ...	[ 0, 0, 0 ]	5	[ 2, 2, 0, 2, 0 ]	intervention 1: AMG 479 at 12 mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 12 mg/kg IV monotherapy for up to 24 months from study ...	intervention 1: AMG 479 intervention 2: AMG 479 intervention 3: Carboplatin intervention 4: AMG 479 intervention 5: Paclitaxel	25	Fayetteville \| Arkansas \| United States \| -94.15743 \| 36.06258 Fayetteville \| Arkansas \| United States \| -94.15743 \| 36.06258 Fort Wayne \| Indiana \| United States \| -85.12886 \| 41.1306 Fort Wayne \| Indiana \| United States \| -85.12886 \| 41.1306 Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838 Indianapolis \|...	14	NCT00807612	6TERMINATED	2010-08-01	2009-01-01	NantCell, Inc.	4INDUSTRY	true	true	false	https://cdn.clinicaltrials.gov/large-docs/12/NCT00807612/Prot_SAP_000.pdf	0
[ 3 ]	155	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.	null	Irritable Bowel Syndrome		null	3	arm 1: A high dose of LX1031; daily oral intake for 28 days arm 2: A low dose of LX1031; daily oral intake for 28 days arm 3: Matching placebo dosing with daily oral intake	[ 0, 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: A high dose of LX1031; daily oral intake for 28 days intervention 2: A low dose of LX1031; daily oral intake for 28 days. intervention 3: Matching placebo dosing with daily oral intake	intervention 1: LX1031 High Dose intervention 2: LX1031 Low Dose intervention 3: Placebo	36	Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Sherwood \| Arkansas \| United States \| -92.22432 \| 34.81509 Anaheim \| California \| United States \| -117.9145 \| 33.83529 Fountain Valley \| California \| United States \| -117.95367 \| 33.70918 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Orange \| C...	155	NCT00813098	1COMPLETED	2010-08-01	2008-12-01	Lexicon Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 0 ]	36	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The data collected through this pilot study will allow us to increase our understanding of cancer cachexia and the effect of Eicosapentaenoic Acid (EPA) on cancer cachexia. Our long-term goal is to improve nutritional treatment and reduce illness in the cancer patient population.	People who have cancer can get what is called cancer cachexia (CC). The symptoms of CC include getting full quickly when eating (early satiety), loss of appetite, weakness resulting in weight loss and loss of lean body mass. Even a weight loss of 5% in cancer patients reflects poor health, hospitalization, and a higher...	Cancer Cachexia	n-3 fatty acids nutritional treatment molecular pathogenesis	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Participants will receive Lovaza at a dose of 4 g for 6 weeks. Participants will be examined at six weeks for change in protein status as indicated by change in morphological (Height, weight, body mass index, body composition, lean body mass, body fat %), and biochemical (serum prealbumin) markers of pr...	intervention 1: Eicosapentaenoic Acid	2	Stuart \| Florida \| United States \| -80.25283 \| 27.19755 Tampa \| Florida \| United States \| -82.45843 \| 27.94752	36	NCT00815685	1COMPLETED	2010-08-01	2007-07-01	H. Lee Moffitt Cancer Center and Research Institute	7OTHER	false	false	false	null	0
[ 3 ]	53	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	To assess whether two doses of dabigatran etexilate (110 mg twice daily (b.i.d) and 150 mg twice daily (b.i.d)) as compared to unfractionated heparin (UFH), both in addition to a standard dual antiplatelet regimen, provide sufficient anticoagulation in the setting of elective percutaneous coronary intervention (PCI).	null	Heart Catheterization		null	3	arm 1: experimental drug therapy in this indication arm 2: experimental drug therapy in this indication arm 3: standard therapy in this indication as comparator	[ 0, 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: comparison of different dabigatran dosages with unfractionated heparin intervention 2: comparison of different dabigatran dosages with unfractionated heparin intervention 3: comparison of different dosages dabigatran with unfractionated heparin	intervention 1: dabigatran 110 mg intervention 2: dabigatran 150 mg intervention 3: unfractionated heparin	4	Alkmaar \| N/A \| Netherlands \| 4.74861 \| 52.63167 Nieuwegein \| N/A \| Netherlands \| 5.08056 \| 52.02917 Rotterdam \| N/A \| Netherlands \| 4.47917 \| 51.9225 Rotterdam \| N/A \| Netherlands \| 4.47917 \| 51.9225	51	NCT00818753	1COMPLETED	2010-08-01	2009-01-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0
[ 3 ]	432	RANDOMIZED	PARALLEL	1PREVENTION	2DOUBLE	false	0ALL	null	The 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled core study investigated the prophylactic effect of canakinumab on the signs and symptoms of acute flares in chronic gout patients initiating allopurinol therapy. The core study was followed by a 24-week open-label, multicenter extens...	null	Gout	Gout Chronic gout Gouty arthritis Gout flares	null	11	arm 1: Canakinumab 25 mg subcutaneously (sc) once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol w...	[ 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: Canakinumab was supplied in glass vials as a lyophilized powder. intervention 2: 0.5 mg capsule orally once daily for 16 weeks. intervention 3: 100-300 mg orally once daily for 24 weeks. intervention 4: Subcutaneous injection. intervention 5: Capsule orally once daily for 16 weeks.	intervention 1: Canakinumab intervention 2: Colchicine intervention 3: Allopurinol intervention 4: Placebo Matching Canakinumab intervention 5: Placebo Matching Colchicine	89	Huntington Beach \| California \| United States \| -117.99923 \| 33.6603 San Diego \| California \| United States \| -117.16472 \| 32.71571 Jupiter \| Florida \| United States \| -80.09421 \| 26.93422 Honolulu \| Hawaii \| United States \| -157.85833 \| 21.30694 Overland Park \| Kansas \| United States \| -94.67079 \| 38.98223 Topeka \| Ka...	772	NCT00819585	1COMPLETED	2010-08-01	2008-12-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 4 ]	103	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	This study will test the hypothesis that sequential injection of 1.5% mepivacaine followed 90 seconds later by 0.5% ropivacaine in ultrasound guided supraclavicular block provides a quicker onset and a longer duration of analgesia than an equi-dose mixture of the two local anesthetics.	Patients will be randomized into one of two groups, Group M: Ropivacaine and Mepivacaine - subject will receive two injections before surgery begins. These two injections will consist of the mixture of mepivacaine (15 ml) and ropivacaine (15 ml). Group S: Mepivacaine followed by Ropivacaine. Subjects will receive two ...	Local Anesthetic	surgery for arm hand or elbow mepivacaine ropivacaine hand surgery elbow surgery forearm surgery	null	2	arm 1: combined group: ropivacaine and mepivacaine mixture: 1:1 volume mixture of 1.5% mepivacaine and 0.5% ropivacaine in 2 syringes (labeled 1 and 2) with 15 mL in each (total, 30 mL) injected in immediate sequence; arm 2: sequential group: mepivacaine followed by ropivacaine: syringe 1 containing 15 mL of 1.5% mepiv...	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: ropivacaine (15 ml). intervention 2: One syringe will contain mepivacaine (15 ml)	intervention 1: Ropivacaine intervention 2: Mepivacaine	1	Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995	103	NCT00825786	1COMPLETED	2010-08-01	2008-09-01	The Cleveland Clinic	7OTHER	false	false	false	null	0
[ 4 ]	164	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The present trial is set up to evaluate the efficacy and safety of 4.0 mg.kg-1 sugammadex in Chinese and Caucasian subjects for registration purposes in China.	null	Anesthesia, General Neuromuscular Blockade		null	2	arm 1: At 1-2 post-tetanic counts (PTC) after the last dose of rocuronium, 4.0 mg.kg-1 sugammadex was to be administered. Caucasian subjects living in Europe. arm 2: At 1-2 post-tetanic counts (PTC) after the last dose of rocuronium, 4.0 mg.kg-1 sugammadex was to be administered. Chinese subjects living in China.	[ 0, 0 ]	1	[ 0 ]	intervention 1: After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammad...	intervention 1: Sugammadex	0	null	151	NCT00826176	1COMPLETED	2010-08-01	2010-01-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0
[ 3 ]	10	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	This is an 8-week, open-labe study of memantine in the treatment of compulsive buying.	The goal of the proposed study is to evaluate the efficacy of memantine in the treatment of compulsive buying. Sixteen subjects meeting criteria for compulsive buying will receive 8 weeks of open-label memantine. The hypothesis to be tested is that memantine will be effective and well tolerated in patients with compuls...	Compulsive Buying	Buying Shopping Impulse Control	null	1	arm 1: 10-30mg, memantine	[ 0 ]	1	[ 0 ]	intervention 1: 10-30mg, by mouth, daily	intervention 1: Memantine	2	Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997 Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997	10	NCT00830375	1COMPLETED	2010-08-01	2008-12-01	University of Minnesota	7OTHER	false	false	false	null	0
[ 3 ]	116	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity	null	Type 2 Diabetes Mellitus		null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Tablets, Oral, 5 mg, once daily, 12 weeks intervention 2: Tablets, Oral, 0 mg, Once daily, 12 weeks	intervention 1: Dapagliflozin intervention 2: Placebo	3	San Diego \| California \| United States \| -117.16472 \| 32.71571 Baton Rouge \| Louisiana \| United States \| -91.18747 \| 30.44332 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	44	NCT00831779	1COMPLETED	2010-08-01	2009-04-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 2 ]	16	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	true	0ALL	true	Aims: 1. Does inflammation contribute importantly to concurrent defects in vascular and metabolic dysfunction in human pre-diabetic obesity? 2. Are there benefits of anti-inflammatory treatment strategies in pre-diabetic obesity in the context of existing treatment with metformin? 3. Are there benefits of anti-inflamm...	We set out to pursue the following Aims: 1. Does inflammation contribute importantly to concurrent defects in vascular and metabolic dysfunction in human pre-diabetic obesity? Pilot studies were performed exploring the acute actions of salsalate on vascular function, the chronic actions of salasate in obese individual...	Pre-diabetes Obesity	Vascular function Glucose tolerance Obesity Pre-diabetes	null	3	arm 1: Nondiabetic lean and obese subjects will be studied in this arm. Subjects will be studied at baseline and after a single dose of oral salsalate. arm 2: Obese subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate. arm 3: Lean subjects will be ...	[ 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses. intervention 2: Subjects will receive a single oral dose of 2 gram of oral salsalate	intervention 1: Chronic salsalate intervention 2: Acute Salsalate	1	Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838	16	NCT00837590	6TERMINATED	2010-08-01	2009-03-01	Indiana University	7OTHER	false	false	false	null	0
[ 5 ]	65	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This single-arm, open-label, multi-center study enrolled 65 patients from approximately 20 centers. All patients who met the study criteria and were taking, beginning or resuming treatment with Deferasirox were allowed. The study will began with a one month run-in phase, where all patients were instructed to take Defer...	Following the run-in phase, patients entered a three month, assessment phase. During the assessment phase, patients were given five general options for taking Deferasirox including with or without meals, crushed and added to a soft food or mixed in a liquid of choice.	Transfusional Hemosiderosis	Exjade deferasirox palatability tolerability food iron overload Serum Iron overload due to transfusions	null	1	arm 1: Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.	[ 0 ]	1	[ 0 ]	intervention 1: Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.	intervention 1: deferasirox:	23	Oakland \| California \| United States \| -122.2708 \| 37.80437 Palo Alto \| California \| United States \| -122.14302 \| 37.44188 Pleasant Hill \| California \| United States \| -122.0608 \| 37.94798 Aurora \| Colorado \| United States \| -104.83192 \| 39.72943 New Haven \| Connecticut \| United States \| -72.92816 \| 41.30815 Augusta \| ...	265	NCT00845871	1COMPLETED	2010-08-01	2009-05-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 0 ]	1	NA	SINGLE_GROUP	7BASIC_SCIENCE	0NONE	false	1FEMALE	true	The purpose of this study is to establish the utility of lapatinib in the treatment of DCIS, particularly ER-negative DCIS.	Ductal carcinoma in situ (DCIS) of the breast is a pre-malignant lesion of the breast, which is associated with a marked increase in the likelihood of developing invasive breast cancer. Since DCIS tends to be associated with microcalcifications, it is detected with an increased frequency in patients being screened with...	Ductal Carcinoma in Situ	DCIS breast	null	0	null	null	1	[ 0 ]	intervention 1: 1500 mg lapatinib for 14-21 days	intervention 1: lapatinib	1	Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838	1	NCT00857714	6TERMINATED	2010-08-01	2009-04-01	Indiana University	7OTHER	false	false	false	null	0
[ 2, 3 ]	17	RANDOMIZED	CROSSOVER	0TREATMENT	0NONE	true	0ALL	false	This is a phase I, open-label, controlled drug interaction study to determine the effects of darunavir plus ritonavir on the pharmacokinetics of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, rosuvastatin, in HIV-1-seronegative subjects.	Twelve HIV-negative healthy volunteers will be randomized to one of two groups. Group 1 would receive rosuvastatin 10mg daily (Treatment A) in interval 1 for 7 days, followed by a washout period of at least 7 days. In interval 2, darunavir/ritonavir 600/100mg bid (Treatment B) would be administered for 7 days, followed...	HIV Infections	HIV dyslipidemia statins protease inhibitors	null	2	arm 1: Darunavir+ritonavir x 7 days; Rosuvastatin x 7 days; Combination x 7 days arm 2: Rosuvastatin x 7 days; darunavir+ritonavir x 7 days; Combination x 7 days	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: darunavir 600 mg twice daily for 7 days ritonavir 100 mg twice daily for 7 days rosuvastatin 10 mg once daily for 7 days Combination of all three drugs for 7 days intervention 2: rosuvastatin 10 mg daily for 7 days; darunavir 600 mg twice daily for 7 days with ritonavir 100 mg twice daily for 7 days; Co...	intervention 1: darunavir, ritonavir, rosuvastatin intervention 2: rosuvastatin, darunavir, ritonavir	1	Cincinnati \| Ohio \| United States \| -84.51439 \| 39.12711	41	NCT00885495	1COMPLETED	2010-08-01	2009-01-01	University of Cincinnati	7OTHER	false	false	false	null	0
[ 3 ]	15	NA	SINGLE_GROUP	4SUPPORTIVE_CARE	0NONE	false	1FEMALE	false	To characterize the effects of discontinuation of denosumab therapy on variables of bone histology in postmenopausal women with low bone mass or osteoporosis. Patients who have received denosumab and completed study 20050179 (NCT00293813), completed study 20050141 (NCT00330460), completed study 20060237 (NCT00515463), ...	null	Low Bone Mass Low Bone Mineral Density Osteoporosis Postmenopausal Osteoporosis	Low Bone Mass Low Bone Mineral Density Osteoporosis Postmenopausal Osteoporosis Bone Biopsy Transiliac Crest Bone Histology Histomorphometry	null	1	arm 1: Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.	[ 5 ]	1	[ 0 ]	intervention 1: Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.	intervention 1: Previous denosumab	0	null	15	NCT00887965	1COMPLETED	2010-08-01	2009-06-01	Amgen	4INDUSTRY	false	false	false	null	0
[ 4 ]	86	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine.	This study was terminated on May 7, 2010 due to modification of the dimebon development plan following the lack of demonstration of efficacy in the completed DIM14 (CONNECTION) Study. The study was not terminated due to any safety findings. Dimebon has been well-tolerated in clinical trials. Demonstration of efficacy f...	Alzheimer Disease	Alzheimer disease moderate-to-severe memantine safety and efficacy	null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Dimebon 10 mg po TID for 1 week followed by Dimebon 20 mg TID for 25 weeks intervention 2: Placebo (matched to Dimebon) po for 26 weeks	intervention 1: Dimebon 20 mg po TID intervention 2: Placebo po TID	47	Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Costa Mesa \| California \| United States \| -117.91867 \| 33.64113 Encino \| California \| United States \| -118.50119 \| 34.15917 Los Alamitos \| California \| United States \| -118.07256 \| 33.80307 Newport Beach \| California \| United States \| -117.92895 \| 33.61891 Newpo...	86	NCT00912288	6TERMINATED	2010-08-01	2009-09-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 3 ]	1	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	BL22 is a type of protein that scientists have created to interact with certain cancer cells. Experiments have shown that BL22 can bind with cancer cells that have a particular kind of protein (called CD22 ) on their surface, and can kill those cells. CD22 is present on certain types of hairy cell leukemia (HCL) cancer...	Background: BL22, also called CAT-3888 or RFB4(dsFv)-PE38, is a recombinant immunotoxin containing an Fv fragment of an anti-CD22 monoclonal antibody and truncated Pseudomonas exotoxin (PE). In Phase 1 and 2 trials in patients with chemoresistant hairy cell leukemia (HCL), BL22 showed 47-61% complete remission (CR) r...	Hairy Cell Leukemia	BL22 in HCL after Immunotoxin Hairy Cell Leukemia Leukemia	null	1	arm 1: 30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.	[ 0 ]	1	[ 0 ]	intervention 1: 30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.	intervention 1: BL22 (CAT-3888)	1	Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067	1	NCT00924040	6TERMINATED	2010-08-01	2009-02-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0
[ 4 ]	16	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	1FEMALE	true	EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).	The purpose of the study is to determine whether the addition of the experimental mucinous glycoprotein 1 (MUC1) antigen-specific cancer immunotherapy tecemotide (L-BLP25) to hormonal treatment is effective in prolonging progression-free survival in postmenopausal women with endocrine-sensitive inoperable locally advan...	Breast Cancer	Phase III trial randomized cancer vaccine MUC1 BLP25 advanced breast cancer postmenopausal breast cancer immunotherapy of breast cancer Inoperable locally advanced, recurrent, or metastatic endocrine-sensitive Breast Cancer	null	2	arm 1: Investigational Arm: * Pretreatment (Single Dose): 300 milligrams per square meter (mg/m\^2) up to a maximum dose of 600 mg of intravenous cyclophosphamide * tecemotide (L-BLP25) plus Hormonal Therapy (Standard Dose) arm 2: Control Arm: * Pretreatment (Single Dose): sodium chloride (NaCl) 9 grams per liter (g/...	[ 0, 1 ]	4	[ 2, 2, 0, 0 ]	intervention 1: Investigational Arm: Pretreatment (Single Dose) 300 mg/m\^2 of intravenous cyclophosphamide in investigational arm to a maximum of 600 milligrams (mg). Primary treatment phase: Hormonal treatment plus 8 consecutive weekly subcutaneous vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual del...	intervention 1: Tecemotide (L-BLP25) and Hormonal Treatment intervention 2: Placebo of tecemotide (L-BLP25) and Hormonal Treatment intervention 3: cyclophosphamide intervention 4: sodium chloride (NaCl)	29	Hickory \| North Carolina \| United States \| -81.3412 \| 35.73319 Bedford Park, SA \| N/A \| Australia \| 138.56815 \| -35.02204 Innsbruck \| N/A \| Austria \| 11.39454 \| 47.26266 Salzburg \| N/A \| Austria \| 13.04399 \| 47.79941 Leuven \| N/A \| Belgium \| 4.70093 \| 50.87959 Pardubice \| N/A \| Czechia \| 15.77659 \| 50.04075 Prague \| N/...	16	NCT00925548	6TERMINATED	2010-08-01	2009-09-01	EMD Serono	4INDUSTRY	false	false	false	null	0
[ 5 ]	56	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The aim of the study is to quantify postoperative pain after functional endoscopic sinus surgery (FESS) and investigate whether preemptive analgesia may positively impact intraoperative anesthetic management, decrease patient postoperative pain and discomfort, and improve patient functional outcomes.	The sphenopalatine ganglion block (SPGB) with local anesthetic is used to treat facial pain and headache of various etiologies and has been widely used during functional endoscopic sinus surgery (FESS). The purpose of this study was to investigate whether preemptive SPGB may positively impact postoperative pain and fun...	Pain, Postoperative		null	2	arm 1: 3 ml of 0.25% Bupivacaine with Epi 1:100,000 (A block) arm 2: Normal saline with Epi 1:100,000 (B block)	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Bupivacaine local anesthesia block prior to start of FESS procedure. intervention 2: placebo is identical in appearance in comparison to active drug.	intervention 1: Bupivacaine Block intervention 2: Placebo	1	Stanford \| California \| United States \| -122.16608 \| 37.42411	56	NCT00927888	1COMPLETED	2010-08-01	2007-08-01	Stanford University	7OTHER	false	false	false	null	0
[ 3 ]	16	RANDOMIZED	CROSSOVER	0TREATMENT	4QUADRUPLE	false	0ALL	true	Mucus clearance is impaired in cystic fibrosis. Inhaled surfactants may reduce adhesive forces between mucus and airway surfaces and improve mucus clearance. This in turn my improve lung health. The investigators propose to measure mucus clearance before and after lucinactant or vehicle administration in patients with ...	This single-center pilot study is designed as a double-blind, randomized, cross-over clinical trial to evaluate the effects of inhaled lucinactant, an investigational peptide-containing synthetic surfactant (6 ml of 20 mg total phospholipid (TPL)/mL solution x 5 doses) in patients with mild to moderate CF lung disease....	Cystic Fibrosis		null	2	arm 1: Active treatment first, then washout period, then placebo treatment arm 2: 0.9% NaCl vehicle treatment first, then washout period, then lucinactant treatment	[ 5, 5 ]	2	[ 0, 0 ]	intervention 1: lucinactant 120 mg (20 mg/ml) x 5 doses over 24 hours, then washout period x 14 days, then vehicle x 5 doses over 24 hrs intervention 2: 6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours	intervention 1: Lucinactant first intervention 2: Placebo first	1	Chapel Hill \| North Carolina \| United States \| -79.05584 \| 35.9132	31	NCT00934362	1COMPLETED	2010-08-01	2008-10-01	University of North Carolina, Chapel Hill	7OTHER	false	false	false	null	0
[ 2 ]	41	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	The objective of this trial is to investigate the pharmacokinetics and pharmacodynamics of linagliptin (BI 1356) 5 mg administered orally in patients with Type 2 diabetes mellitus of African American origin.	null	Diabetes Mellitus, Type 2		null	1	arm 1: Pharmacokinetic (PK)/Pharmacodynamic (PD) investigation	[ 0 ]	1	[ 0 ]	intervention 1: dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration	intervention 1: linagliptin QD (once daily) for 7 days	6	Cypress \| California \| United States \| -118.03729 \| 33.81696 DeLand \| Florida \| United States \| -81.30312 \| 29.02832 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038 New York \| New York \| United States \| -74.00597 \| 40.71427 Dallas \| Texas \| United State...	41	NCT00935220	1COMPLETED	2010-08-01	2009-06-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0
[ 4 ]	326	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.	null	Nocturia		null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Nasal Spray, once a day intervention 2: Nasal Spray	intervention 1: SER120 intervention 2: Placebo	1	New York \| New York \| United States \| -74.00597 \| 40.71427	326	NCT00937378	1COMPLETED	2010-08-01	2009-06-01	Serenity Pharmaceuticals, Inc.	4INDUSTRY	false	false	false	null	0
[ 5 ]	862	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to compare whether Symbicort Maintenance \& Reliever Therapy (SMART) is more effective in uncontrolled asthmatic patients than their current therapy in a real life situation.	null	Asthma	Symbicort SMART	null	1	arm 1: Symbicort Turbuhaler 160/4.5 µg delivered dose	[ 0 ]	1	[ 0 ]	intervention 1: Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms	intervention 1: Symbicort (Budesonide/Formoterol)	35	Guangzhou \| Guangdong \| China \| 113.25 \| 23.11667 Zheng Ahou \| Henan \| China \| N/A \| N/A Wuhan \| Hubei \| China \| 114.26667 \| 30.58333 Changsha \| Hunan \| China \| 112.97087 \| 28.19874 Qingdao \| Shandong \| China \| 120.38042 \| 36.06488 Shanghai \| Shanghai Municipality \| China \| 121.45806 \| 31.22222 Beijing \| N/A \| China \| ...	862	NCT00939341	1COMPLETED	2010-08-01	2009-07-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 4 ]	649	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to evaluate the long-term safety and tolerability of Dimebon in patients with Alzheimer's disease.	This study was terminated on May 7, 2010 as part of modification of the dimebon development plan following lack of demonstration of efficacy in the completed DIM14 (CONNECTION) Study. The study was not terminated due to any safety findings. Dimebon has been well -tolerated in clinical trials. Demonstration of efficacy ...	Alzheimer's Disease		null	1	arm 1: 10 mg TID for Week 1, followed by 20 mg TID for remainder of study	[ 0 ]	1	[ 0 ]	intervention 1: Tablet for oral administration	intervention 1: Dimebon	105	Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Northport \| Alabama \| United States \| -87.57723 \| 33.22901 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Oceanside \| California \| United States \| -117.37948 \| 33.19587 San Diego \| California \| United States \| -117.16472 \| 32.71571 Santa Rosa \| Cali...	648	NCT00939783	6TERMINATED	2010-08-01	2009-09-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 4 ]	803	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with irritable bowel syndrome with constipation (IBS-C). The primary efficacy parameter is the percentage of patients in each treatment group that meet the protocol definition for Abdominal Pain and Complete Spo...	null	Irritable Bowel Syndrome Characterized by Constipation	Irritable Bowel Syndrome Constipation Linaclotide	null	2	arm 1: Linaclotide 290 micrograms arm 2: Matching placebo	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study intervention 2: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study	intervention 1: Linaclotide 290 micrograms intervention 2: Matching placebo	118	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Hueytown \| Alabama \| United States \| -86.99666 \| 33.45122 Huntsville \| Alabama \| United States \| -86.58594 \| 34.7304 Chandler \| Arizona \| United States \| -111.84125 \| 33.30616 Mesa \| Arizona \| United ...	1,447	NCT00948818	1COMPLETED	2010-08-01	2009-07-01	Forest Laboratories	4INDUSTRY	false	false	false	null	0
[ 3 ]	838	RANDOMIZED	PARALLEL	7BASIC_SCIENCE	4QUADRUPLE	false	0ALL	true	The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.	null	Chronic Obstructive Pulmonary Disease	Chronic Obstructive Pulmonary Lung Respiratory disease Efficacy Safety and tolerability Placebo-controlled Pharmacokinetics COPD	null	4	arm 1: AZD9668 active treatment arm 2: AZD9668 active treatment arm 3: AZD9668 active treatment arm 4: AZD9668 placebo treatment	[ 1, 1, 1, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 2 x 30 mg oral tablets twice daily (bid) for 12 weeks intervention 2: 2 x 10 mg oral tablets twice daily (bid) for 12 weeks intervention 3: 2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks intervention 4: 2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks	intervention 1: AZD9668 intervention 2: AZD9668 intervention 3: AZD9668 intervention 4: AZD9668 Placebo	105	Fullerton \| California \| United States \| -117.92534 \| 33.87029 Valparaiso \| Indiana \| United States \| -87.06114 \| 41.47309 Council Bluffs \| Iowa \| United States \| -95.86083 \| 41.26194 Hickory \| North Carolina \| United States \| -81.3412 \| 35.73319 Jefferson Hills \| Pennsylvania \| United States \| -79.93199 \| 40.29118 Gaf...	838	NCT00949975	1COMPLETED	2010-08-01	2009-07-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 5 ]	28	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	true	0ALL	false	The main purpose of this study is to evaluate the effect of desvenlafaxine administered as DVS SR on the pharmacokinetics of midazolam in healthy male and female subjects. The amount of drug in the body and the effect of the drug will also be evaluated.	null	Major Depressive Disorder	depression	null	1	arm 1: None	[ 0 ]	2	[ 0, 0 ]	intervention 1: 50 mg DVS SR tablet days 1-6, period 2 only. intervention 2: 4 mg midazolam (2 mL midazolam syrup) day 1, period 1 and day 6, period 2.	intervention 1: Desvenlafaxine Succinate Sustained Release intervention 2: Midazolam	1	New Haven \| Connecticut \| United States \| -72.92816 \| 41.30815	84	NCT00952653	1COMPLETED	2010-08-01	2010-06-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 3 ]	15	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	Marijuana is the most commonly used illicit drug in the United States. However, the treatment options for cannabis dependence are limited; notably, no effective pharmacotherapy has been developed. Conceptually, the ideal medication treatment for cannabis dependence would: 1. be safe when administered to patients activ...	Conceptually, the pharmacodynamic and clinical actions of quetiapine suggest that it may be useful for cannabis dependence. By antagonizing dopamine, quetiapine may interfere with the reinforcing effects of cannabis, while serotonin type 2A, histamine type 1, and adrenergic receptor antagonism may reduce cannabis withd...	Cannabis Dependence	Cannabis quetiapine	null	1	arm 1: Open label treatment with quetiapine	[ 0 ]	1	[ 0 ]	intervention 1: Quetiapine treatment from 25 mg daily to 300 mg twice daily	intervention 1: quetiapine	1	New York \| New York \| United States \| -74.00597 \| 40.71427	15	NCT00954681	1COMPLETED	2010-08-01	2009-08-01	New York State Psychiatric Institute	7OTHER	false	false	false	null	0
[ 5 ]	89	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily to the upper eyelid margins (where the eyelashes meet the skin) compared with vehicle in increasing overall eyelash prominence in self-identified African American/ethnic black subjects exhibiting hypotrichosis of the eyelashes (in...	null	Hypotrichosis		null	2	arm 1: bimatoprost ophthalmic 0.03% solution arm 2: vehicle sterile solution	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Apply one drop of study medication along the upper eyelid margin once daily in the evening intervention 2: Apply one drop of study medication along the upper eyelid margin once daily in the evening	intervention 1: bimatoprost ophthalmic 0.03% solution intervention 2: vehicle sterile solution (placebo)	1	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	89	NCT00958035	1COMPLETED	2010-08-01	2009-11-01	Allergan	4INDUSTRY	false	false	false	null	0
[ 3 ]	161	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	This study is a six-month, prospective, randomized, multicenter, single- blind, controlled clinical study to evaluate the effect of three low-doses of Naturlose (Tagatose) on glycemic control and safety in subjects with Type 2 diabetes under diet control and exercise. The subjects were randomized in one of the 3 arms r...	Screening (Visit 1) and Run-in Period This period of the study was designed as an 8-week screening and stabilization period, during which potentially eligible subjects participated in a weight-maintaining diet and a daily exercise program. Subjects who were eligible for screening were diabetic subjects treated solely...	Type 2 Diabetes		null	3	arm 1: 2.5 Active - 2.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months. arm 2: 5.0 mid dose - 5.0 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months. arm 3: 7.5 high dose - 7.5 g D-tagatose given orally, three times daily, immediately prior to me...	[ 0, 1, 1 ]	1	[ 0 ]	intervention 1: powder to be dissolved in water prior to dosage.	intervention 1: D-Tagatose	13	Garden Grove \| California \| United States \| -117.94145 \| 33.77391 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Decatur \| Georgia \| United States \| -84.29631 \| 33.77483 Houston \| Texas \| United States \| -95.36327 \| 29.76328 Patna \| Bihar \| India \| 85.13563...	145	NCT00961662	1COMPLETED	2010-08-01	2008-02-01	Robert Lodder	4INDUSTRY	false	false	false	null	0
[ 3 ]	18	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	Part I was a double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study to evaluate the safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrations of LDE225 (a specific Smoothened inhibitor) on skin basal cell carcinomas in Gorlin's syndrome patients. Following...	null	Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients	Basal Cell Carcinoma Gorlin Syndrome, Gorlin-Goltz Syndrome, Basal Cell Nevus Syndrome, Nevoid Basal Cell Carcinoma Syndrome, Basal Cell Carcinoma Nevus Syndrome	null	4	arm 1: Participants were exposed to both topically applied 0.75% LDE225 cream and LDE225 vehicle cream twice daily for 28 days where each treatment was randomized to two different test areas on each participant. arm 2: Participants were exposed to both topically applied 0.75% LDE225 cream and LDE225 vehicle cream twice...	[ 1, 2, 1, 1 ]	3	[ 0, 0, 0 ]	intervention 1: Placebo cream intervention 2: None intervention 3: None	intervention 1: Vehicle intervention 2: LDE225 0.25% intervention 3: LDE225 0.75%	3	Graz \| N/A \| Austria \| 15.45 \| 47.06667 Vienna \| N/A \| Austria \| 16.37208 \| 48.20849 Zurich \| N/A \| Switzerland \| 8.55 \| 47.36667	18	NCT00961896	1COMPLETED	2010-08-01	2009-07-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 0 ]	60	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The objective of this prospective, randomized, double-blind, parallel-group, placebo-controlled study is to determine the effectiveness of intranasal oxytocin in subjects suffering from chronic daily headache.	The TI004 and TI005 studies both used a randomized, double-blind, placebo-controlled, parallel-group study design. A protocol-specified interim analysis was performed after completion of the first 40 subjects, resulting in termination of the TI004 study and development of the TI005 protocol, which included the followin...	Chronic Daily Headache	intranasal oxytocin acute headache treatment chronic daily headache	null	4	arm 1: Treated group arm 2: Placebo group arm 3: None arm 4: None	[ 0, 2, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 4 actuations in each nostril for a total dose of 32 IU intervention 2: 4 actuations in each nostril intervention 3: 8 actuations in each nostril for a total dose of 64 IU intervention 4: 8 actuations in each nostril	intervention 1: Syntocinon intervention 2: Sterile water intervention 3: Syntocinon intervention 4: Sterile water	1	Wellesley Hills \| Massachusetts \| United States \| -71.27867 \| 42.30843	60	NCT00963040	1COMPLETED	2010-08-01	2009-11-01	MedVadis Research Corporation	4INDUSTRY	false	false	false	null	0
[ 0 ]	32	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The hypothesis of this study is that by using 3 injections of EUFLEXXA, there will be an improvement in pain levels and range of motion.	To demonstrate that EUFLEXXA is safe for the treatment of chronic shoulder pain associated with osteoarthritis.	Osteoarthritis		null	1	arm 1: ACTIVE CONTROL	[ 0 ]	1	[ 0 ]	intervention 1: 2.5 mL of EUFLEXXA (per injection) x 3 injections	intervention 1: EUFLEXXA	1	Marietta \| Georgia \| United States \| -84.54993 \| 33.9526	32	NCT00969501	1COMPLETED	2010-08-01	2009-08-01	Georgia Institute for Clinical Research, LLC	7OTHER	false	false	false	null	0
[ 4 ]	82	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The main objective of the study is to evaluate the effectiveness, tolerability, and safety of tapentadol hydrochloride prolonged release (PR) in participants suffering from severe chronic pain due to osteoarthritis of the knee who are taking WHO Step III analgesics and show lack of tolerability. This is a clinical effe...	The trial will last up to 13 weeks for each subject and includes: * One week of observation under previous analgesic treatment. * Twelve weeks of treatment with tapentadol hydrochloride PR.	Chronic Pain Osteoarthritis	Osteoarthritis pain assessment tapentadol centrally acting analgesic	null	1	arm 1: Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.	[ 0 ]	1	[ 0 ]	intervention 1: Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg, 100 mg or 150 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not per...	intervention 1: Tapentadol PR	24	Melbourne \| N/A \| Australia \| 144.96332 \| -37.814 Perth \| N/A \| Australia \| 115.8614 \| -31.95224 Aalborg \| N/A \| Denmark \| 9.9187 \| 57.048 Hvidovre \| N/A \| Denmark \| 12.47708 \| 55.64297 Kolding \| N/A \| Denmark \| 9.47216 \| 55.4904 Odense \| N/A \| Denmark \| 10.38831 \| 55.39594 Vejle \| N/A \| Denmark \| 9.5357 \| 55.70927 Ber...	63	NCT00982280	6TERMINATED	2010-08-01	2009-09-01	Grünenthal GmbH	4INDUSTRY	false	false	false	null	0
[ 5 ]	196	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	The purpose of this study is to determine if the agent, Floseal, can decrease the amount of blood patients lose after total knee replacement (TKR) surgery. If this product can be found to have an effect on bleeding, it may potentially reduce the problems associated with bleeding after knee replacement surgery such as p...	This is a prospective double blind randomized clinical trial of patients requiring unilateral total knee arthroplasty. The patients will be randomized intra-operatively to receiving Floseal or no treatment. Both the patient and the observers will be blinded to whether the subject received Floseal or no treatment. Only...	Blood Loss	To decrease blood loss during knee surgery	null	2	arm 1: 2 vials of Floseal applied once at the end of surgery arm 2: No intervention.	[ 0, 4 ]	1	[ 0 ]	intervention 1: FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze s...	intervention 1: Hemostatic Matrix	1	New York \| New York \| United States \| -74.00597 \| 40.71427	196	NCT00990288	1COMPLETED	2010-08-01	2007-10-01	Hospital for Special Surgery, New York	7OTHER	false	false	false	null	0
[ 4 ]	406	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This study is being conducted to compare the safety and efficacy of loteprednol etabonate compared to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.	null	Inflammation Pain		null	2	arm 1: Loteprednol etabonate arm 2: Vehicle of loteprednol etabonate	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days. intervention 2: 1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.	intervention 1: Vehicle of Loteprednol Etabonate intervention 2: Loteprednol Etabonate	1	Rochester \| New York \| United States \| -77.61556 \| 43.15478	406	NCT01010633	1COMPLETED	2010-08-01	2009-11-01	Bausch & Lomb Incorporated	4INDUSTRY	false	false	false	null	0
[ 3 ]	8	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	In this study, we will evaluate clinical activity, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of 5 LY2525623 dosing groups compared to placebo in adults with plaque psoriasis.	null	Psoriasis	Psoriasis	null	7	arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None arm 7: None	[ 0, 2, 2, 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: administered intravenously at randomization and every 2 weeks for 6 weeks intervention 2: administered subcutaneously at randomization and every 2 weeks for 6 weeks intervention 3: administered intravenously at randomization and every 2 weeks for 6 weeks intervention 4: administered subcutaneously at ra...	intervention 1: LY2525623 Intravenous intervention 2: LY2525623 Subcutaneous intervention 3: Placebo Intravenous intervention 4: Placebo Subcutaneous	28	Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Peoria \| Arizona \| United States \| -112.23738 \| 33.5806 Hot Springs \| Arkansas \| United States \| -93.05518 \| 34.5037 Fremont \| California \| United States \| -121.98857 \| 37.54827 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 San Diego \| Californi...	8	NCT01018810	6TERMINATED	2010-08-01	2009-12-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0
[ 3 ]	615	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD	null	Chronic Obstructive Pulmonary Disease (COPD)	Chronic obstructive pulmonary lung respiratory disease efficacy placebo-controlled COPD FEV1 St Georges Respiratory Questionnaire	null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 2 x 30 mg oral tablets bd for 12 weeks intervention 2: 2 x matched placebo to oral tablet bd for 12 weeks	intervention 1: AZD9668 intervention 2: Placebo	66	Lovech \| N/A \| Bulgaria \| 24.71667 \| 43.13333 Pleven \| N/A \| Bulgaria \| 24.61667 \| 43.41667 Plovdiv \| N/A \| Bulgaria \| 24.75 \| 42.15 Rousse \| N/A \| Bulgaria \| 25.9534 \| 43.84872 Sofia \| N/A \| Bulgaria \| 23.32415 \| 42.69751 Stara Zagora \| N/A \| Bulgaria \| 25.64194 \| 42.43278 Troyan Municipality \| N/A \| Bulgaria \| 24.715...	615	NCT01023516	1COMPLETED	2010-08-01	2009-11-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 3 ]	401	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	This study will investigate the safety and efficacy of a new formulation of an existing medication for the treatment of papulopustular rosacea. The study will test the active ingredient plus foam against foam alone.	null	Papulopustular Rosacea	rosacea papulopustular azelaic acid foam	null	2	arm 1: Participants received azelaic acid foam, 15% topically twice daily for 12 weeks arm 2: Participants received vehicle foam topically twice daily for 12 weeks	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Applied topically twice daily for 12 weeks intervention 2: Applied topically twice daily for 12 weeks	intervention 1: Azelaic acid foam 15% intervention 2: Vehicle foam	20	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Fremont \| California \| United States \| -121.98857 \| 37.54827 Santa Monica \| California \| United States \| -118.49138 \| 34.01949 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Miramar \| Florida ...	401	NCT01025635	1COMPLETED	2010-08-01	2009-12-01	LEO Pharma	4INDUSTRY	false	false	false	null	0
[ 5 ]	32	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	true	1FEMALE	false	This study aims to evaluate head-to-head the effectiveness of tretinoin 0.5% and superficial dermabrasion in subjects that have recent stretch marks.	Healthy female subjects, from 11 t0 25 years old, that have thin (1-5mm) recent(less than 6 months of evolution),reddish or purple line stretch marks. The striae should be symmetrical and it could be located in the abdomen,breasts, upper arms, thighs (both inner and outer), hips, and buttocks. Thirty subjects will be ...	Stretch Marks Striae Treatment	Stretch marks Striae Tretinoin Superficial dermabrasion	null	2	arm 1: Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks. arm 2: Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.	[ 1, 1 ]	2	[ 0, 1 ]	intervention 1: Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks. intervention 2: Group 2 will receive 16 sessions of dermabrasion that would be held in the research center	intervention 1: Tretinoin cream 0.005% intervention 2: Superficial Dermabrasion	1	Porto Alegre \| Rio Grande do Sul \| Brazil \| -51.23019 \| -30.03283	22	NCT01027793	1COMPLETED	2010-08-01	2009-03-01	Brazilan Center for Studies in Dermatology	7OTHER	false	false	false	null	0
[ 3 ]	128	RANDOMIZED	CROSSOVER	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to evaluate the efficacy of this multicenter, randomized, double-blind, placebo-controlled, 4-period, incomplete-block crossover, dose-ranging study comparing 2 fixed dose combinations (FDCs) of aclidinium bromide with formoterol fumarate or with placebo, aclidinium bromide and formoterol f...	null	Chronic Obstructive Pulmonary Disease	Chronic Obstructive Pulmonary Disease COPD Chronic Bronchitis Emphysema Airflow Obstruction, Chronic Chronic Airflow Obstruction Chronic Obstructive Airway Disease Chronic Obstructive Lung Disease	null	5	arm 1: Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) arm 2: Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) arm 3: Aclidinium bromide 400 μg administered twice-daily (BID) arm 4: Formoterol fumarate ...	[ 0, 0, 0, 1, 2 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods. intervention 2: Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day...	intervention 1: Aclidinium 400 μg / Formoterol 12 μg intervention 2: Aclidinium 400 μg / Formoterol 6 μg intervention 3: Aclidinium 400 μg intervention 4: Formoterol 12 μg intervention 5: Placebo	20	Glendale \| Arizona \| United States \| -112.18599 \| 33.53865 Pheonix \| Arizona \| United States \| N/A \| N/A Rancho Mirage \| California \| United States \| -116.41279 \| 33.73974 Stockton \| California \| United States \| -121.29078 \| 37.9577 Wheat Ridge \| Colorado \| United States \| -105.07721 \| 39.7661 Clearwater \| Florida \| Un...	456	NCT01049360	1COMPLETED	2010-08-01	2009-12-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 4 ]	7	NA	SINGLE_GROUP	2DIAGNOSTIC	0NONE	false	0ALL	true	This study will determine the level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical estimates of amyloid levels in biopsy samples previously obtained during shunt placement in patients who have normal pressure hydrocephalus (NPH).	null	Normal Pressure Hydrocephalus	Amyloid NPH Normal pressure hydrocephalus PET Positron Emission Tomography SUVR Standard uptake value ratios	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: All subjects will receive an intravenous (IV) dose of \[18F\]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 megabecquerels (MBq).	intervention 1: [18F] Flutemetamol	1	Princeton \| New Jersey \| United States \| -74.65905 \| 40.34872	7	NCT01053312	1COMPLETED	2010-08-01	2009-12-01	GE Healthcare	4INDUSTRY	false	false	false	null	0
[ 3 ]	84	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) effects of SP-304 in patients with chronic idiopathic constipation.	This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, PK and PD effects of SP-304 in patients with chronic idiopathic constipation. Patients diagnosed with chronic idiopathic constipation (CIC) will be screened for the anticipated 4 cohorts, to...	Chronic Idiopathic Constipation	Chronic Idiopathic Constipation Constipation Irritable Bowel Syndrome	null	5	arm 1: SP-304 0.3 mg tablet by mouth once daily for 14 consecutive days. arm 2: SP-304 1.0 mg tablet by mouth once daily for 14 consecutive days. arm 3: SP-304 3.0 mg tablet by mouth once daily for 14 consecutive days arm 4: SP-304 9.0 mg tablet by mouth once daily for 14 consecutive days. arm 5: Placebo tablet by mout...	[ 0, 0, 0, 0, 2 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: SP-304 0.3 mg intervention 2: SP-304 1.0 mg intervention 3: SP-304 3.0 mg intervention 4: SP-304 9.0 mg intervention 5: Placebo	intervention 1: SP-304 0.3 mg intervention 2: SP-304 1.0 mg intervention 3: SP-304 3.0 mg intervention 4: SP-304 9.0 mg intervention 5: Placebo	14	Mesa \| Arizona \| United States \| -111.82264 \| 33.42227 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Anaheim \| California \| United States \| -117.9145 \| 33.83529 Orange \| California \| United States \| -117.85311 \| 33.78779 Hialeah \| Florida \| United States \| -80.27811 \| 25.8576 Miami \| Florida \| United States ...	78	NCT01053962	1COMPLETED	2010-08-01	2010-03-01	Bausch Health Americas, Inc.	4INDUSTRY	false	false	false	null	0
[ 3 ]	255	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	To evaluate efficacy and safety of additional dose of celecoxib, as compared to placebo, in patients with post lateral mandibular impacted third molar tooth extraction pain.	null	Pain	Acute pain after oral surgery lateral mandibular Impacted third molar tooth extraction	null	3	arm 1: None arm 2: None arm 3: None	[ 0, 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with "moderate pain" or "severe pain"rated as 45.0 mm or more on the VAS intervention 2: Additional dose: Celecoxib 200mg tablet x 1 ...	intervention 1: Celecoxib intervention 2: Celecoxib intervention 3: Placebo	22	Niihama-shi \| Ehime \| Japan \| N/A \| N/A Kitakyusyu-shi \| Fukuoka \| Japan \| N/A \| N/A Takasaki-shi \| Gunma \| Japan \| N/A \| N/A Kure-shi \| Hiroshima \| Japan \| N/A \| N/A Kanazawa \| Ishikawa-ken \| Japan \| 136.61667 \| 36.6 Kita-gun \| Kagawa-ken \| Japan \| N/A \| N/A Isehara-shi \| Kanagawa \| Japan \| N/A \| N/A Kumamoto \| Kumamo...	255	NCT01062113	1COMPLETED	2010-08-01	2010-04-01	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	4INDUSTRY	false	false	false	null	0
[ 3 ]	246	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated on different background diabetes therapies.	null	Type 2 Diabetes Mellitus Impaired Glucose Tolerance	Type 2 Diabetes Mellitus canakinumab Pre diabetic glucose intolerant oral anti diabetic medication insulin treatment metabolic syndrome	null	10	arm 1: Eligible participants received a single subcutaneous injection Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening arm 2: Eligible participants received a s...	[ 0, 2, 0, 2, 0, 2, 0, 2, 0, 2 ]	2	[ 0, 0 ]	intervention 1: Single subcutaneous injection of Canakinumab 150 mg. intervention 2: Single subcutaneous injection of Placebo to Canakinumab.	intervention 1: Canakinumab 150 mg intervention 2: Placebo to Canakinumab	52	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Santa Ana \| California \| United States \| -117.86783 \| 33.74557 Spring Valley \| California \| United States \| -116.99892 \| 32.74477 Madisonville \| Kentucky \| United States \| -87.49889 \| 37.3281 Omaha \| Nebraska \| United States \| -95.94043 \| 41.25626 Omaha \|...	244	NCT01068860	1COMPLETED	2010-08-01	2010-02-01	Novartis	4INDUSTRY	false	false	false	null	0
[ 4 ]	99	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to evaluate the effect of MP-513 on 24-h glycemic control in patients with type 2 Diabetes for 4 weeks administration.	null	Type 2 Diabetes Mellitus	insulin resistance	null	3	arm 1: None arm 2: None arm 3: None	[ 0, 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: MP-513 10 mg, once a day, for 4 weeks intervention 2: MP-513 20 mg, once a day, for 4 weeks intervention 3: MP-513 placebo, once a day, for 4 weeks	intervention 1: MP-513 intervention 2: MP-513 intervention 3: Placebo of MP-513	1	Suita \| Osaka \| Japan \| 135.51567 \| 34.76143	99	NCT01072331	1COMPLETED	2010-08-01	2010-02-01	Mitsubishi Tanabe Pharma Corporation	4INDUSTRY	false	false	false	null	0
[ 3 ]	7	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	The purpose of this study is to determine whether a homeopathic therapy in combination with cyclosporin (Restasis) is more effective than cyclosporin (Restasis) alone in the treatment of dry eye disease.	Dry eye disease affects millions of people world-wide, and presents with symptoms of blurred vision, discharge from the eyes, eye discomfort, burning, redness, sandy and gritty feeling in the eyes, and sensitivity to light. Topical eye drops for eye lubrication (i.e., artificial tear solutions) and controlling ocular i...	Dry Eye Syndromes	Dry Eye Syndromes Lacrimal Apparatus Diseases	null	2	arm 1: Subjects will receive Euphrasia-based homeopathic therapy (Artificial Tears) in combination with cyclosporin solution (Restasis) . arm 2: Subjects will receive placebo in combination with cyclosporin solution (Restasis) .	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: ophthalmic solution; 1 drop both eyes twice daily intervention 2: Cyclosporin solution; 1 drop both eyes twice daily	intervention 1: Euphrasia-based homeopathic therapy intervention 2: Cyclosporin solution	1	Columbia \| Missouri \| United States \| -92.33407 \| 38.95171	6	NCT01072526	6TERMINATED	2010-08-01	2007-12-01	University of Missouri-Columbia	7OTHER	false	false	false	null	0
[ 0 ]	10	RANDOMIZED	CROSSOVER	7BASIC_SCIENCE	2DOUBLE	true	0ALL	false	Previous studies have shown that the beta-adrenergic system plays a role in processing pain and the expression of hyperalgesia. Recent studies have investigated the analgesic effects, and potential anti-hyperalgesic effects (using a model of opioid induced (OIH) hyperalgesia) of propranolol, a beta adrenergic antagonis...	This study is a double blind-placebo controlled study in which subjects will be exposed to propranolol infusion during one study day, the opioid alfentanil on another day, and placebo infusion during a third study day. The infusion order will be randomized, and the participant and individual conducting the pain testing...	Pain Measurement		null	3	arm 1: Experimental inflammation, and tissue injury sites were created, an infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally. arm 2: Experimental inflammation and tissue injury sit...	[ 1, 1, 2 ]	3	[ 0, 0, 0 ]	intervention 1: An infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump. intervention 2: An infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump. intervention 3: An infusion of normal saline was administered over 3 hours using a pro...	intervention 1: Alfentanil intervention 2: Propranolol intervention 3: Placebo	1	Stanford \| California \| United States \| -122.16608 \| 37.42411	10	NCT01094574	1COMPLETED	2010-08-01	2010-01-01	Martin Angst	7OTHER	false	false	false	null	0
[ 4 ]	335	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	This study will compare the pain relieving effect of a single-dose of a novel ibuprofen formulation to placebo and two formulations of standard ibuprofen in the treatment of post-surgical dental pain following "wisdom" tooth (third molar) removal.	null	Pain	Pain following third molar extraction	null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 0, 1, 1, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Single-dose of novel ibuprofen (equal to 400 mg ibuprofen) intervention 2: Single-dose of standard ibuprofen (400mg) intervention 3: Single-dose of standard ibuprofen (400mg) intervention 4: Single-dose of placebo	intervention 1: Novel Ibuprofen intervention 2: Standard Ibuprofen intervention 3: Standard Ibuprofen intervention 4: Placebo	0	null	316	NCT01098747	1COMPLETED	2010-08-01	2010-04-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 4 ]	61	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Open-label, 8 week study, to assess the efficacy and safety of oral Budesonide-MMX 9 mg Extended-release Tablets in patients with mild to moderate, active ulcerative colitis who are not in remission based on the Ulcerative Colitis Disease Activity Index in study CB-01-02/01 (parent study \[NCT00679432\]).	Patients who complete the parent study and who do not achieve clinical remission will be eligible to receive 8 weeks of open-label treatment with Budesonide-MMX 9mg if they satisfy the entry criteria for this study.	Colitis, Ulcerative	ulcerative colitis Budesonide	null	1	arm 1: Budesonide-MMX 9 mg tablet	[ 0 ]	1	[ 0 ]	intervention 1: One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.	intervention 1: Budesonide	15	Andhra Pradesh \| N/A \| India \| N/A \| N/A Andhra Pradesh \| N/A \| India \| N/A \| N/A Andhra Pradesh \| N/A \| India \| N/A \| N/A Andhra Pradesh \| N/A \| India \| N/A \| N/A Assam \| N/A \| India \| N/A \| N/A Gujarat \| N/A \| India \| N/A \| N/A Karnataka \| N/A \| India \| N/A \| N/A Karnataka \| N/A \| India \| N/A \| N/A Kerala \| N/A \| Ind...	60	NCT01100112	1COMPLETED	2010-08-01	2010-02-01	Bausch Health Americas, Inc.	4INDUSTRY	false	false	false	null	0
[ 3 ]	101	RANDOMIZED	PARALLEL	1PREVENTION	2DOUBLE	false	0ALL	false	The purpose of this study is to evaluate the efficacy of loteprednol etabonate ophthalmic base, compared to loteprednol etabonate ophthalmic suspension, and vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in a modified Conjunctival Allergen Challenge model and in an environmental model du...	null	Allergic Conjunctivitis		null	5	arm 1: Loteprednol etabonate ophthalmic base dosed once/day. arm 2: Loteprednol etabonate ophthalmic base dosed two times/day arm 3: Loteprednol etabonate ophthalmic base dosed four times/day. arm 4: Loteprednol etabonate ophthalmic suspension dosed four times/day arm 5: Vehicle of loteprednol etabonate, dosed either Q...	[ 1, 1, 1, 1, 2 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks intervention 2: Loteprednol etabonate ophthalmic base BID dosing for 2 weeks intervention 3: Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week intervention 4: Loteprednol etabonate ophthalmic suspension dosed four t...	intervention 1: Loteprednol etabonate base (QD) intervention 2: Loteprednol etabonate base (BID) intervention 3: Loteprednol etabonate base (QID) intervention 4: Loteprednol etabonate suspension intervention 5: Vehicle of loteprednol etabonate	1	Rochester \| New York \| United States \| -77.61556 \| 43.15478	101	NCT01107405	1COMPLETED	2010-08-01	2010-04-01	Bausch & Lomb Incorporated	4INDUSTRY	false	false	false	null	0
[ 4 ]	16	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This is a study in a small population of children who have inborn errors of bile acid synthesis who are currently taking established doses of the currently used cholic acid capsules prepared at the Cincinnati Children's Hospital Pharmacy. The study is designed to compare the efficacy of these currently used capsules wi...	Bile acids are end products of cholesterol metabolism. Individuals with inborn errors of bile acid synthesis lack the enzymes needed to synthesize the primary bile acids cholic acid and chenodeoxycholic acid (CDCA). These conditions are serious and account for approximately 1% of cases presenting as idiopathic cholesta...	Inborn Errors of Bile Acid Synthesis	Inborn Errors Bile Acid Pediatrics Liver Disease	null	1	arm 1: Manufactured cholic acid capsules	[ 0 ]	1	[ 0 ]	intervention 1: The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid. Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 o...	intervention 1: Cholic acid	1	Cincinnati \| Ohio \| United States \| -84.51439 \| 39.12711	16	NCT01115582	1COMPLETED	2010-08-01	2010-04-01	Mirum Pharmaceuticals, Inc.	4INDUSTRY	false	false	false	null	0
[ 3 ]	79	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	0ALL	false	The present trial is conducted to further assess the efficacy by means of serial spirometry, safety and tolerability of three doses of aclidinium bromide administered twice a day compared to previously approved BID drug, formoterol 12 µg, and placebo in patients with moderate to severe chronic obstructive pulmonary dis...	null	Chronic Obstructive Pulmonary Disease (COPD)	COPD	null	5	arm 1: Aclidininum bromide 100 μg twice daily by inhalation arm 2: Aclidininum bromide 200 μg twice daily by inhalation arm 3: Aclidininum bromide 400 μg twice daily by inhalation arm 4: Placebo twice-daily by inhalation arm 5: Formoterol 12 μg twice daily by inhalation	[ 0, 0, 0, 2, 1 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days intervention 2: Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days intervention 3: Aclidinium bromide 4...	intervention 1: Aclidinium bromide 100 μg bid intervention 2: Aclidinium bromide 200 μg bid intervention 3: Aclidininum bromide 400 μg bid intervention 4: Placebo intervention 5: Formoterol 12 μg bid	11	Ghent \| N/A \| Belgium \| 3.71667 \| 51.05 Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Frankfurt \| N/A \| Germany \| 10.53333 \| 49.68333 Groβhansdorf \| N/A \| Germany \| N/A \| N/A Hamburg \| N/A \| Germany \| 9.99302 \| 53.55073 Hanover \| N...	370	NCT01120093	1COMPLETED	2010-08-01	2010-05-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 2 ]	41	RANDOMIZED	CROSSOVER	0TREATMENT	0NONE	true	0ALL	false	This study will compare how the body treats 2 different forms of insulin lispro and how they affect blood sugar levels.	The 2 formulations of insulin lispro will be referred to here as: Lispro A Lispro B	Healthy Volunteers	insulin lispro	null	2	arm 1: 20 units (U) subcutaneously (SC) arm 2: 20 units (U) subcutaneously (SC)	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 20 units (U) subcutaneously (SC). intervention 2: 20 U subcutaneously (SC).	intervention 1: Insulin lispro A intervention 2: Insulin lispro B	1	Singapore \| N/A \| Singapore \| 103.85007 \| 1.28967	75	NCT01133392	1COMPLETED	2010-08-01	2010-05-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0
[ 5 ]	11	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The proposed study will evaluate the potential benefit of a tapered course of hydrocortisone compared to abrupt cessation in patients initiated on hydrocortisone for septic shock. The study will include adult patients in the medical intensive care unit (MICU) who meet criteria for corticosteroid therapy for septic shoc...	Current therapy for septic shock includes antimicrobials, fluid resuscitation, catecholamines, and measures to improve tissue oxygen delivery. The use of corticosteroids as an adjunctive treatment in septic shock has been an area of intensive research over the past decade. A handful of studies suggest that patients in ...	Septic Shock	Sepsis hydrocortisone	null	2	arm 1: Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days) arm 2: 0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 1\) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days) intervention 2: 0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortison...	intervention 1: hydrocortisone intervention 2: Normal Saline	1	Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995	11	NCT01150409	6TERMINATED	2010-08-01	2008-05-01	The Cleveland Clinic	7OTHER	false	false	false	null	0
[ 2 ]	32	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	true	0ALL	null	This clinical trial is intended to investigate a possible effect of the p-gp inhibitor ketoconazole on the bioavailability of olodaterol	null	Healthy Pulmonary Disease, Chronic Obstructive		null	2	arm 1: solution for oral inhalation arm 2: tablet	[ 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 10 mcg solution for oral inhalation intervention 2: 10 mcg solution for oral inhalation intervention 3: 400 mg tablet intervention 4: 400 mg tablet	intervention 1: BI 1744 intervention 2: BI 1744 intervention 3: Ketoconazole intervention 4: Ketoconazole	1	Ingelheim \| N/A \| Germany \| 8.05883 \| 49.97078	64	NCT01153711	1COMPLETED	2010-08-01	2010-05-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0
[ 2 ]	40	NON_RANDOMIZED	PARALLEL	1PREVENTION	0NONE	true	0ALL	false	The hypothesis of this study is that up to 150 mg of sertraline and up to 3 mg of telenzepine will be safe, tolerable, and have the effect of suppressing appetite, when taken in combination daily by mouth by healthy, overweight, adult men and women. In this study, up to 12 people will be assigned to one of 4 groups: A...	null	Obesity	Obesity Overweight Sertraline Telenzepine Decrease appetite Reduce appetite Lose weight	null	4	arm 1: Group A: No Sertraline; 0, 1, 2, 3 mg/day Telenzepine arm 2: Sertraline 50 mg/day; 0, 1, 2, 3 mg/day Telenzepine arm 3: Sertraline 50, 100 mg/day; 0, 1, 2, 3 mg/day Telenzepine arm 4: Sertraline 50, 100, 150 mg/day; 0, 1, 2, 3 mg/day Telenzepine	[ 0, 0, 0, 0 ]	1	[ 0 ]	intervention 1: oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination	intervention 1: Sertraline plus Telenzepine	0	null	40	NCT01155531	1COMPLETED	2010-08-01	2010-05-01	Theracos	4INDUSTRY	false	false	false	null	0
[ 5 ]	215	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.	null	Allergic Conjunctivitis	Allergic conjunctivitis	null	1	arm 1: 1 drop self-administered in each eye once daily in the morning for 7 days	[ 0 ]	1	[ 0 ]	intervention 1: Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis	intervention 1: Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)	0	null	215	NCT01159769	1COMPLETED	2010-08-01	2010-06-01	Alcon Research	4INDUSTRY	false	false	false	null	0
[ 2 ]	20	RANDOMIZED	CROSSOVER	null	0NONE	true	0ALL	true	Clopidogrel, in combination with aspirin, is currently the recommended treatment for secondary prevention of ischemic events in high-risk patients and for prevention of coronary artery stent thrombosis. Patients receiving aspirin and clopidogrel are frequently treated with proton pump inhibitors, such as omeprazole or ...	Clopidogrel, in combination with aspirin, is currently the recommended treatment for secondary prevention of ischemic events in high-risk patients and for prevention of coronary artery stent thrombosis. Patients receiving aspirin and clopidogrel are frequently treated with proton pump inhibitors, such as omeprazole or ...	Drug Interaction	proton pump inhibitor clopidogrel platelet function	null	2	arm 1: prospective, open-label, two-sequence, three-period, randomized crossover study arm 2: prospective, open-label, two-sequence, three-period, randomized crossover study	[ 1, 1 ]	1	[ 0 ]	intervention 1: The clopidogrel dose will be a 600mg loading dose followed by a 75mg daily maintenance dose, starting the next day for 7 days. Omeprazole will be used at a daily dose of 40mg and pantoprazole at 80mg.	intervention 1: omeprazole and pantoprazole	1	Jacksonville \| Florida \| United States \| -81.65565 \| 30.33218	40	NCT01170533	1COMPLETED	2010-08-01	2009-03-01	University of Florida	7OTHER	false	false	false	null	0
[ 4 ]	89	RANDOMIZED	PARALLEL	1PREVENTION	3TRIPLE	true	0ALL	true	This is a research study on Altitude Illness. From the information collected and studied in this project we hope to learn more about Altitude Illness, including factors that may affect and prevent the development and progression of this condition. We hope to learn if the commonly used non-steroidal anti-inflammatory me...	This study was designed to bring together elements of prior studies and go one step further for definitive data on several points. The trial will employ two pharmaceutical intervention arms, which will compare placebo (the standard of care - information on prevention of altitude sickness) with the widely used NSAID ibu...	Altitude Sickness		null	2	arm 1: 600mg ibu TID arm 2: visually identical	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: 3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total) intervention 2: identical number of visually identical tasteless pills as ibuprofen arm	intervention 1: Ibuprofen intervention 2: Placebo	1	Stanford \| California \| United States \| -122.16608 \| 37.42411	89	NCT01171794	1COMPLETED	2010-08-01	2010-07-01	Stanford University	7OTHER	false	false	false	null	0
[ 0 ]	20	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	This is an investigator-blinded, prospective study of 20 subjects aged 13 through 18 with mild to moderate acne. Study subjects will be randomized to an internet survey group, in which an email link for a survey ascertaining the status of the subject's acne is sent weekly, or to a control group. All study subjects will...	null	Acne Vulgaris	Acne Acne vulgaris Adherence Compliance MEMS Benzoyl peroxide	null	2	arm 1: Subjects will receive a weekly email link to complete an internet survey about their acne and use of the study medication. arm 2: Subjects will receive standard-of-care treatment with the study medication, without internet surveys.	[ 0, 2 ]	2	[ 5, 0 ]	intervention 1: A weekly email link will be generated to an internet survey which questions subjects about their acne severity, compliance with the study medication, and attitudes toward acne and the study medication. intervention 2: Topical benzoyl peroxide 5% gel, to be used once daily to the face.	intervention 1: Internet survey intervention 2: Benzoyl peroxide 5% gel	1	Winston-Salem \| North Carolina \| United States \| -80.24422 \| 36.09986	20	NCT01176955	1COMPLETED	2010-08-01	2009-05-01	Wake Forest University	7OTHER	false	false	false	null	0
[ 5 ]	40	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	The purpose of this study is to evaluate the antibacterial activity of Epiduo® Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel) on P. acnes compared to that of Benzoyl Peroxide 2.5% Gel.	null	Acne Vulgaris	P. acnes, Acne vulgaris	null	2	arm 1: * Dose or Concentration:Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel. * Mode and Frequency of Administration:Topical to the face, once daily application in the evening. * Duration of Treatment:12 weeks arm 2: * Dose or Concentration:Adapalene 0% / Benzoyl Peroxide 2.5% Gel. * Mode and Frequency of Administration:T...	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Once daily application on the face in the evening for 12 weeks intervention 2: Once daily application on the face in the evening for 12 weeks	intervention 1: Epiduo gel intervention 2: BPO	1	Iwonicz-Zdrój \| N/A \| Poland \| 21.78992 \| 49.56319	40	NCT01188538	1COMPLETED	2010-08-01	2010-03-01	Galderma R&D	4INDUSTRY	false	false	false	null	0
[ 5 ]	27	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	false	This is a Phase IV, pilot, open-label, national, multi-centric study planned to determine the gene expression profiles and histologic changes of the endometrial tissue before and after stimulation with Gonal-f®. Physicians are interested in identifying predictive genetic markers in assisted reproductive technologies (A...	This is a pilot open-label, national, multi-centre, Phase IV trial. This trial will be conducted with outpatients. Once subject has met all eligibility criteria, she will be treated with Gonal-f® prefilled pen and will receive on a randomization basis the GnRH agonist or antagonist. The follicle stimulating hormone (FS...	In Vitro Fertilization	Infertility Gonal-f gene expression Assisted Reproductive Technologies Follitropin alfa endometrium	null	2	arm 1: None arm 2: None	[ 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed. intervention 2: Ovulation triggering will be performed using a single injection o...	intervention 1: Gonal -f® [r-hFSH] intervention 2: Ovitrelle® [r-hCG alfa] intervention 3: Gonadotropin-releasing hormone (GnRH) Agonist intervention 4: Gonadotropin-releasing hormone (GnRH) Antagonist	1	Paris \| N/A \| France \| 2.3488 \| 48.85341	24	NCT01210144	6TERMINATED	2010-08-01	2008-08-01	Merck KGaA, Darmstadt, Germany	4INDUSTRY	false	false	false	null	0
[ 2, 3 ]	89	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	The purpose of this study is to examine the safety and efficacy of bepotastine besilate nasal product in seasonal allergic rhinitis patients.	null	Seasonal Allergic Rhinitis		null	4	arm 1: bepotastine besilate nasal product - low dose arm 2: bepotastine besilate nasal product - medium dose arm 3: bepotastine besilate nasal product - high dose arm 4: placebo comparator nasal product	[ 0, 0, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: sterile nasal product intervention 2: sterile nasal product intervention 3: sterile nasal product intervention 4: sterile nasal product	intervention 1: bepotastine besilate nasal product - low dose intervention 2: bepotastine besilate nasal product - medium dose intervention 3: bepotastine besilate nasal product - high dose intervention 4: placebo comparator nasal product	1	Irvine \| California \| United States \| -117.82311 \| 33.66946	89	NCT01222299	1COMPLETED	2010-08-01	2010-05-01	Bausch & Lomb Incorporated	4INDUSTRY	false	false	false	null	0
[ 3 ]	43	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This open-label study will assess the efficacy and safety of Avastin (bevacizumab) plus Xeloda (capecitabine) in combination with standard technique radiotherapy of the pelvic region in the neo-adjuvant setting in patients with locally advanced primary rectal cancer. Patients will receive 4 courses of Avastin at a dose...	null	Colorectal Cancer		null	1	arm 1: None	[ 0 ]	7	[ 0, 0, 4, 3, 0, 0, 0 ]	intervention 1: 5 mg/kg intravenously every 2 weeks, 4 cycles intervention 2: 825 mg/m2 twice daily orally, 38 days intervention 3: Total dose of 45 Gy over 38 days intervention 4: 6-8 weeks after completion of neoadjuvant treatment intervention 5: Post-surgery adjuvant treatment at the discretion of the investigator: ...	intervention 1: bevacizumab [Avastin] intervention 2: capecitabine [Xeloda] intervention 3: Radiation therapy intervention 4: Mesorectal excision intervention 5: bevacizumab [Avastin] intervention 6: 5-fluorouracil intervention 7: leucovorin	9	Ancona \| N/A \| Italy \| 13.5103 \| 43.60717 Bologna \| N/A \| Italy \| 11.33875 \| 44.49381 Cuneo \| N/A \| Italy \| 7.54828 \| 44.39071 Genova \| N/A \| Italy \| 11.87211 \| 45.21604 Napoli \| N/A \| Italy \| 14.5195 \| 40.87618 Paola \| N/A \| Italy \| 16.03691 \| 39.36313 Pisa \| N/A \| Italy \| 10.4036 \| 43.70853 Roma \| N/A \| Italy \| 11.10...	42	NCT01227707	1COMPLETED	2010-08-01	2005-11-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0
[ 0 ]	14	RANDOMIZED	CROSSOVER	null	2DOUBLE	false	0ALL	false	The addition of an inhaled long-acting beta-adrenergic agonist to an inhaled glucocorticosteroid improves disease control in persistent asthma. This observation has supported the use of long-acting beta-adrenergic agonist/glucocorticosteroid combination preparations for the management of asthma. Currently, salmeterol/f...	Fourteen lifetime nonsmokers with a physician diagnosis of asthma will be recruited for the study. All subjects will be allowed to use short-acting beta-adrenergic agonists as rescue medication. Inclusion criteria: 1. Males and females, 18 to 65 years of age. 2. FEV1 60-85% of predicted on the screening day. Exclusi...	Asthma	asthma, corticosteroids, bronchodilator, airway blood flow	null	4	arm 1: participants were treated fluticasone/salmeterol, arm 2: participants were treated with salmeterol arm 3: participants were treated with fluticasone arm 4: participants were treated with placebo	[ 0, 0, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 220- mcg once intervention 2: placebo inhalation once intervention 3: 50 mcg salmeterol once intervention 4: inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol	intervention 1: fluticasone intervention 2: placebo inhalation intervention 3: Salmeterol intervention 4: fluticasone/salmeterol	0	null	56	NCT01231230	1COMPLETED	2010-08-01	2007-05-01	University of Miami	7OTHER	false	false	false	null	0
[ 2 ]	24	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	true	0ALL	false	Compare the DHE pharmacokinetic profiles observed following administration of: 1. MAP0004 (oral inhalation DHE) 2. MAP0004 co-administered with oral Ketoconazole 3. Intravenous (IV) DHE (D.H.E.45®, the approved reference therapy) Compare the tolerability of MAP0004, IV DHE, and MAP0004 with co-administration of Ketoc...	null	Healthy	Drug Drug Interaction Study in Normal Healthy Volunteers	null	1	arm 1: Subjects received MAP0004 on Day 1 of Visit 2, Ketoconazole on Days 3 through 6 of Visit 2, and MAP0004 again on Day 6 of Visit 2. Subjects then returned for Visit 3, 7-11 days from the end of Visit 2. At Visit 3 subjects received 1.0 mg IV DHE (Intravenous Dihydroergotamine Mesylate).	[ 5 ]	3	[ 0, 0, 0 ]	intervention 1: MAP0004 1.0mg via inhalation on Day 1 and Day 6 of Visit 2 intervention 2: IV DHE (Intravenous Dihydroergotamine Mesylate) administered at Visit 3 intervention 3: Ketoconazole 400 mg administered once a day on days 3-6 of Visit 2	intervention 1: MAP0004 intervention 2: IV DHE intervention 3: Ketoconazole	1	Merthyr Tydfil \| Merthyr Tydfil \| United Kingdom \| -3.37779 \| 51.74794	70	NCT01468558	1COMPLETED	2010-08-01	2010-07-01	Allergan	4INDUSTRY	false	false	false	null	0
[ 2 ]	25	RANDOMIZED	CROSSOVER	0TREATMENT	0NONE	true	0ALL	false	The purpose of this study is to investigate the effect of rasagiline on BIA 9-1067 pharmacokinetics in healthy subjects.	Single-centre, open-label, randomised, three-way crossover study consisting of 3 single-dose periods separated by a washout of 14 days or more	Parkinson Disease	Parkinson Disease BIA 9-1067	null	3	arm 1: Period 1: 50 mg BIA 9-1067 alone Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg arm 2: Period 1: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 alone Period 3: 50 mg BIA ...	[ 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: 50 mg BIA 9-1067 (single-dose) intervention 2: 1 mg rasagiline (single-dose)	intervention 1: BIA 9-1067 intervention 2: Rasagiline	1	Rennes \| N/A \| France \| -1.67429 \| 48.11198	98	NCT01532141	1COMPLETED	2010-08-01	2009-11-01	Bial - Portela C S.A.	4INDUSTRY	false	false	false	null	0
[ 5 ]	64	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	Hip Fracture (HFx) is a painful injury that is often treated in the Emergency Department (ED) with intravenous opiates. However, this class of medications may cause deleterious side effects. An alternative analgesic approach involves regional anesthesia. The investigators attempted to determine (1) whether ultrasound g...	Hip fracture (HFx) is a painful orthopedic emergency that commonly presents to the Emergency Department (ED). There are approximately 320,000 HFx diagnosed annually in the United States, with this number expected to increase as the population ages. It has previously been shown that patients with pain from HFx are under...	Hip Fracture	Hip Fracture Ultrasound Nerve Block	null	3	arm 1: Ultrasound guided 3 in 1 femoral nerve block: The UFNB was performed by first visualizing the femoral nerve in a transverse orientation just inferior to the inguinal ligament and lateral to the common femoral artery. arm 2: Ultrasound Guided Fascia Iliaca Compartment Block: For the UFIB, the two fascial planes, ...	[ 0, 0, 1 ]	3	[ 3, 3, 0 ]	intervention 1: Ultrasound Guided Femoral Nerve Block intervention 2: None intervention 3: Intravenous Morphine	intervention 1: UFNB (Ultrasound guided femoral nerve block) intervention 2: UFIB (Ultrasound Guided Fascia Iliaca Compartment Block) intervention 3: IVMS (IV Morphine)	1	Brooklyn \| New York \| United States \| -73.94958 \| 40.6501	64	NCT01904071	1COMPLETED	2010-08-01	2008-10-01	Antonios Likourezos	7OTHER	false	false	false	null	0
[ 0 ]	181	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	true	0ALL	null	Parallel, double blind, randomized, Institutional Review Board (IRB) -approved study involving approximately 160 subjects to complete. Subjects were randomly assigned to either the test product (Arm \& Hammer Advance White Brilliant Sparkle) or the control (Crest Cavity Protection Regular) based on baseline mean whole-...	null	Plaque Gingivitis		null	2	arm 1: 2X daily brushing for 12 weeks with Arm \& Hammer Advance White Brilliant Sparkle (Test product). Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks. arm 2: 2X daily brushing for 12 weeks with Crest Cavity Protection Regular Toothpaste (Negative Control). Return to pre-study hygiene...	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 20% sodium bicarbonate intervention 2: Negative control	intervention 1: Arm & Hammer Advance White Brilliant Sparkle (Test product) intervention 2: Crest Cavity Protection Regular Toothpaste (Negative Control)	1	Mississauga \| Ontario \| Canada \| -79.6583 \| 43.5789	181	NCT03214406	1COMPLETED	2010-08-03	2010-02-08	Church & Dwight Company, Inc.	4INDUSTRY	false	false	false	null	0
[ 2, 3 ]	11	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to determine safety, tolerability and maximum tolerated dose of BMS-863233 in subjects advanced and/or Metastatic solid tumors.	null	Advanced Solid Cancers Metastatic Cancer	Advanced and/or Metastatic solid cancers	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months	intervention 1: Cdc7-inhibitor	6	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Detroit \| Michigan \| United States \| -83.04575 \| 42.33143 Toronto \| Ontario \| Canada \| -79.39864 \| 43.70643 Toronto \| Ontario \| Canada \| -79.39864 \| 43.70643 Villejuif \| N/A \| France \| 2.35992 \| 4...	11	NCT00886782	6TERMINATED	2010-08-04	2009-05-31	Bristol-Myers Squibb	4INDUSTRY	false	false	false	null	0
[ 3 ]	246	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	To evaluate the efficacy of SPD489 when used as augmentation to an antidepressant in the treatment of major depressive disorder (MDD) as measured by mean change in total Montgomery-Ǻsberg Depression Rating Scale (MADRS) scores.	null	Major Depressive Disorder		null	2	arm 1: Antidepressant + SPD489 arm 2: Antidepressant + placebo	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks intervention 2: Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks	intervention 1: Antidepressant + SPD489 (lisdexamfetamine dimesylate) intervention 2: Antidepressant + placebo	15	Newport Beach \| California \| United States \| -117.92895 \| 33.61891 San Diego \| California \| United States \| -117.16472 \| 32.71571 Bradenton \| Florida \| United States \| -82.57482 \| 27.49893 Fort Myers \| Florida \| United States \| -81.84059 \| 26.62168 Orlando \| Florida \| United States \| -81.37924 \| 28.53834 Atlanta \| Geor...	173	NCT00905424	1COMPLETED	2010-08-04	2009-07-30	Shire	4INDUSTRY	false	false	false	null	0
[ 3 ]	341	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all the patients, irrespective whether they have an acute flare of gout or not. Patients will b...	null	Gouty Arthritis	Gouty Gouty arthritis Gout flares Anti-interleukin-1β monoclonal antibody	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: None	intervention 1: Canakinumab	45	Seattle \| Washington \| United States \| -122.33207 \| 47.60621 Capital Federal Buenos Aires \| N/A \| Argentina \| N/A \| N/A Jette \| N/A \| Belgium \| 4.33419 \| 50.87309 Barranquilla \| N/A \| Colombia \| -74.78132 \| 10.96854 Bogotá \| N/A \| Colombia \| -74.08175 \| 4.60971 Bucaramanga \| N/A \| Colombia \| -73.11895 \| 7.125 Floridabl...	772	NCT00927810	1COMPLETED	2010-08-04	2009-06-05	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 1 ]	30	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving Abraxane together with lapatinib ...	OBJECTIVES: Primary * Determine the clinical response rate, as measured by clinical exam and imaging studies, in patients with stage I-III breast cancer treated with neoadjuvant Abraxane in combination with lapatinib. Secondary * Determine the pathologic complete response rate in patients treated with this regimen....	Breast Cancer	stage I breast cancer stage II breast cancer stage IIIA breast cancer stage IIIB breast cancer stage IIIC breast cancer	null	1	arm 1: 30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.	[ 0 ]	2	[ 0, 0 ]	intervention 1: Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. intervention 2: 30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats ...	intervention 1: lapatinib ditosylate intervention 2: paclitaxel albumin-stabilized nanoparticle formulation	5	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Joliet \| Illinois \| United States \| -88.0834 \| 41.52519 Olympia Fields \| Illinois \| United States \| -87.67421 \| 41.51337 Lubbock \| Texas \| United States \| -101.85517 \| 33.57786	30	NCT00331630	1COMPLETED	2010-08-05	2006-05-04	Northwestern University	7OTHER	false	false	false	null	0
[ 4 ]	2,340	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	This is a 12-week clinical trial in participants with mixed hyperlipidemia to study the effects of MK-0524B on lipids.The primary hypothesis is that MK-0524B (dosed as MK-0524A coadministered with simvastatin) will be superior to atorvastatin on decreasing the low denisity lipoprotein cholesterol (LDL-C)/high-density l...	null	Mixed Hyperlipidemia		null	6	arm 1: Co-administration of one tablet of MK-0524A (Extended Release \[ER\] niacin/laropiprant \[LRPT\] 1g + one tablet of simvastatin 10 mg for 4 weeks, then co-administration of two tablets of MK-0524A 1g + simvastatin 20 mg for 8 weeks arm 2: Co-administration of one tablet of MK-0524A 1g + one tablet of simvastatin...	[ 0, 0, 1, 1, 1, 1 ]	3	[ 0, 0, 0 ]	intervention 1: None intervention 2: None intervention 3: None	intervention 1: MK-0524A intervention 2: Atorvastatin intervention 3: Simvastatin	0	null	2,339	NCT00289900	1COMPLETED	2010-08-06	2006-01-24	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0
[ 3 ]	65	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This was a Phase 2, international, multicenter, open-label, single-arm trial evaluating Marqibo (VSLI) in adult subjects with: 1) Ph- ALL or lymphoblastic lymphoma in second or greater relapse; or 2) Ph- ALL or lymphoblastic lymphoma who failed 2 or greater treatment lines of anti-leukemia chemotherapy. The original en...	The secondary objectives of this study were to evaluate: * Duration of CR plus CRi * Overall survival * Safety and tolerability	Acute Lymphoblastic Leukemia (ALL)	acute lymphoblastic lymphocytic leukemia leukaemia lukemia leukimia ALL Marqibo Hana Biosciences vincristine liposomal liposome optisome hematology malignancy hematological relapsed anti-leukemia adult chemotherapy	null	1	arm 1: Eligible subjects received study drug at 2.25 mg/m\^2 intravenously via peripheral or central venous access over 60 minutes (± 10 minutes).	[ 0 ]	1	[ 0 ]	intervention 1: Dosing was done every 7 days (± 3 days) on Days 1, 8, 15, and 22 with no less than 4 days between dosing days. Dose calculations were based on body surface area using the subject's height (from Screening) and actual weight for each course.	intervention 1: Marqibo® (vincristine sulfate liposomes injection)	33	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Stanford \| California \| United States \| -122.16608 \| 37.42411 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Atla...	65	NCT00495079	1COMPLETED	2010-08-08	2007-05-01	Spectrum Pharmaceuticals, Inc	4INDUSTRY	false	false	false	null	0
[ 3 ]	399	RANDOMIZED	PARALLEL	1PREVENTION	4QUADRUPLE	false	0ALL	true	Multiple agents have been studied to prevent radiocontrast nephropathy. One of these agents is N-Acetylcysteine. Previous trials to assess N-Acetylcysteine's efficacy in the prevention of contrast nephropathy have been promising. However, previous studies have limited applicability to the Emergency Department (ED) pati...	Out of the approximately 110 million Emergency Department (ED) visits in the United States each year approximately 8.8 million people undergo Contrast-Enhanced Computerized Tomography (CT) studies in United States EDs each year (based on the investigators experience). Radiocontrast nephropathy is a serious potential c...	Radiocontrast Nephropathy	NAC Radiocontrast Nephropathy N-Acetylcysteine RCN RCIN Creatinine Computerized Tomography CT Emergency Department ED	null	2	arm 1: Subjects in this group will receive 3 grams of N-acetylcysteine in 500 cc normal saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 200 mg N-acetylcysteine per hour. This dose will be administered as an infusio...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Experimental: * Before CT: 3 g NAC IV in 500 cc of 0.9% Sodium-chloride * After CT: 200 mg NAC/hour in 0.9% Sodium-chloride at 67 cc/hour for up to 24 hours. intervention 2: Placebo: * Before CT: 500 cc 0.9% Sodium-chloride * After CT: NS at 67 cc/hour for up to 24 hours.	intervention 1: N-Acetylcysteine (NAC) intervention 2: 0.9% Sodium-chloride	1	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	399	NCT00780962	1COMPLETED	2010-08-09	2007-10-16	Beth Israel Deaconess Medical Center	7OTHER	false	false	false	null	0
[ 4 ]	395	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	A study to assess the safety and efficacy of the addition of sitagliptin compared to placebo in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin.	null	Type 2 Diabetes Mellitus		null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks. intervention 2: All participants...	intervention 1: Comparator: Sitagliptin phosphate intervention 2: Comparator: Placebo	0	null	395	NCT00813995	1COMPLETED	2010-08-09	2008-12-09	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0
[ 4 ]	133	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The phase III clinical trial examines the efficacy, safety, and tolerability of the addition of MK0431/ONO-5435 to Japanese patients with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on diet/exercise therapy and voglibose monotherapy	null	Diabetes Mellitus, Non-Insulin-Dependent		null	2	arm 1: None arm 2: None	[ 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: Placebo to sitagliptin once daily for 12 weeks (double-blind period) intervention 2: Sitagliptin/Sitagliptin arm only: Sitagliptin 50 mg once daily orally before breakfast for 12 weeks (double-blind period). Both arms: Sitagliptin 50 mg once daily orally before breakfast for 40 weeks (open-label period...	intervention 1: Comparator: Placebo intervention 2: Sitagliptin intervention 3: Voglibose	0	null	266	NCT00837577	1COMPLETED	2010-08-11	2009-02-05	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0
[ 3 ]	60	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	Studying samples of blood, urine, and tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors learn how genistein or placebo works in patients with bladder cancer. This randomized phase II tria...	PRIMARY OBJECTIVES: I. To measure the effect of G-2535 on EGF-R phosphorylation. Two EGF-R phosphorylation sites with functional significance are phosphotyrosine 992, which is a direct binding site for the PLC-gamma SH2 domain, and phosphotyrosine 1068, a binding site for the Grb2/SH2 domain. The expression of EGF-R a...	Recurrent Bladder Carcinoma Stage I Bladder Cancer AJCC v6 and v7 Stage II Bladder Cancer AJCC v6 and v7 Stage III Bladder Cancer AJCC v6 and v7		null	3	arm 1: Patients receive oral genistein twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy. arm 2: Patients receive oral genistein as in arm I but at a higher dose. One day afte...	[ 0, 0, 2 ]	5	[ 0, 10, 10, 10, 3 ]	intervention 1: Given orally intervention 2: Correlative studies intervention 3: Correlative studies intervention 4: Given orally intervention 5: Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.	intervention 1: Genistein intervention 2: Laboratory Biomarker Analysis intervention 3: Pharmacological Study intervention 4: Placebo Administration intervention 5: Therapeutic Conventional Surgery	10	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Laguna Hills \| California \| United States \| -117.71283 \| 33.61252 Iowa City \| Iowa \| United States \| -91.53017 \| 41.66113 Garden City \| New York \| United States \| -73.6343 \| 40.72677 Rochester \| New York \| United States \| -77.61556 \| 43.15478 San Antonio \| Tex...	60	NCT00118040	1COMPLETED	2010-08-15	2005-06-24	National Cancer Institute (NCI)	0NIH	false	false	false	null	0
[ 4 ]	849	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	Test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis	null	Osteoarthritis	monoclonal antibody RN624 PF-04383119 nerve growth factor anti-nerve growth factor OA pain arthritis	null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 0, 0, 1, 2 ]	4	[ 2, 2, 0, 10 ]	intervention 1: tanezumab 10 mg one dose at weeks 0 and 8 intervention 2: tanezumab 5 mg one dose at weeks 0 and 8 intervention 3: naproxen 1000 mg daily for 16 weeks intervention 4: placebo to match tanezumab and naproxen dosing	intervention 1: tanezumab 10 mg intervention 2: tanezumab 5 mg intervention 3: naproxen intervention 4: placebo	95	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Huntsville \| Alabama \| United States \| -86.58594 \| 34.7304 Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Mesa \| Arizona \| United States \| -111.82264 \| 33.42227 Mesa \| Arizona \| United States \| -111.82264 \| 33.42227 Mesa \| Arizona \| United States \| -1...	840	NCT00863304	1COMPLETED	2010-08-16	2009-06-09	Pfizer	4INDUSTRY	false	false	false	null	0

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.